

CURRICULUM VITAE

Samantha M. Jaglowski MD, MPH

Professor
Department of Medicine
Division of Hematology and Oncology - Medicine
Senior Scientific Director for Industry Relations
CIBMTR MCW

OFFICE ADDRESS:

Froedtert Hospital
9200 W Wisconsin Ave
Milwaukee, WI 53226
Email: sjaglowski@mcw.edu

EDUCATION:

2000 B.S. in Zoology (summa cum laude), Honors in the Liberal Arts, Distinction in Zoology, The Ohio State University, Columbus, OH
2004 M.D., The Ohio State University, Columbus 2000, OH
2004 - 2008 Residency, The Ohio State University, Columbus, OH
2008 - 2010 Hematology-Medical Oncology Fellowship, The Ohio State University, Columbus, OH
2010 - 2011 Hematology-Blood Marrow Transplantation, The Ohio State University, Columbus, OH
2010 - 2012 Masters in Public Health, emphasis in Clinical Investigation, The Ohio State University, Columbus, OH
2021 - 2025 Masters in Business Administration, The Ohio State University, Columbus, OH

FACULTY APPOINTMENTS:

2011 - 2018 Assistant Professor, Internal Medicine, Hematology, The Ohio State University Medical Center, Columbus, OH
2018 - 2022 Clinical Associate Professor, Internal Medicine, Hematology, The Ohio State University Medical Center, Columbus, OH
2022 - 2023 Clinical Professor, Internal Medicine, Hematology, The Ohio State University Medical Center, Columbus, OH

EDUCATIONAL ADMINISTRATIVE APPOINTMENTS:

2010 - 2011 Instructor of Clinical Medicine, Hematology, The Ohio State University Medical Center, Columbus, OH

HOSPITAL AND CLINICAL ADMINISTRATIVE APPOINTMENTS:

2016 - 2021 Clinical Director, Blood and Marrow Transplant Program, The Ohio State University Medical Center, Columbus, OH
2017 - 2021 Medical Director, Clinical Informatics, The Ohio State University Comprehensive Cancer Center, Arthur G. James Cancer Hospital and Richard J. Solove Research Institution, Columbus, OH
2019 - 2022 Associate Division Director, Ambulatory Operations, Hematology, The Ohio State University Medical Center, Columbus, OH
2021 - 2023 Clinical Operations Director, Cellular Therapy Program, The Ohio State University Medical Center, Columbus, OH
2021 - 2023 Associate Director, Quality, BMT/CT Program, The Ohio State University Medical Center, Columbus, OH
2022 - 2023 Associate Division Director, Strategic Growth and Access, Hematology, The Ohio State University Medical Center, Columbus, OH
2022 - 2023 Associate Chief Clinical Informatics Officer-Cancer Informatics Officer, The Ohio State

University Medical Center, Columbus, OH

HOSPITAL STAFF PRIVILEGES:

- 2010 - 2011 Attending Physician, Inpatient Hematology Nurse Practitioner and Hematology 2 (acute leukemia) services, 8 weeks/14 months, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH
- 2011 - 2023 Attending Physician, Ambulatory Marrow Transplant Unit, 1 day/week, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH
- 2011 - 2023 Attending Physician, Inpatient Blood and Marrow Transplant and Hematology 1 (housestaff) services, 6 weeks/12 months, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH
- 08/2013 - 2018 Attending Physician, Long-Term Follow-Up Clinic, 1 day/week, James Cancer Hospital and Solove Research Institute, The Ohio State University, Columbus, OH

SPECIALTY BOARDS AND CERTIFICATION:

<u>Certificates</u>	<u>Issued By</u>	<u>Issue Date</u>	<u>Expiration</u>
Internal Medicine	ABIM	2009	2019
Medical Oncology	ABIM	2011	2031
EPIC Physician Builder Certification		2019	None
EPIC Physician Analytics Certification		2023	None

<u>Licensure</u>	<u>Number</u>	<u>Issue Date</u>	<u>Expiration</u>
Medical License		2010	None
Medical License		2023	2025

AWARDS AND HONORS:

- 06/2000 Phi Beta Kappa
- 06/2001 Letter of Commendation in Medical Humanities
- 06/2001 Arthritis Foundation Grant
- 08/2002 Honors in Psychiatry
- 11/2002 Letter of Commendation in Pediatrics
- 08/2003 Letter of Commendation in Internal Medicine
- 09/2003 Honors in Medical Education
- 01/2004 Honors in Gynecology
- 03/2004 Honors in Pain/Palliative Care
- 06/2010 Outstanding Clinical Care by a Fellow
- 06/2011 ASH Scholar Award
- 06/2011 JCO Young Investigator Award
- 07/2012 ASBMT Clinical Research Training Course
- 08/2012 K12 Scholar
- 07/2013 ASBMT New Investigator Award
- 07/2013 NIH Loan Repayment Award
- 07/2015 NIH Loan Repayment Award
- 03/2017 Circleville High School Alumni Achievement Award
- 01/2018 Michael R Grever, MD Distinguished Scholar Award
- 09/2018 ASH Advocacy Leadership Training Scholar
- 09/2020 NMDP Advocacy Ambassador

MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES:

- 2009 - Present American Society of Clinical Oncology (Member)
- 2010 - Present American Society of Hematology (Member)
- 2010 - Present American Society of Blood and Marrow Transplantation (Member)

2012 - Present Late Effects and Quality of Life Working Committee, CIBMTR (Member)
 2012 - 2013 ASH Scholar Award Study Section (Member)
 2012 - Present Chronic Leukemia Working Committee, CIBMTR (Member)
 2012 - Present Lymphoma Working Committee, CIBMTR (Member)
 2012 - Present Graft-versus-Host Disease Working Committee, CIBMTR (Member)
 2013 - 2018 Chronic Graft-versus-Host Disease Consortium (Member)
 2016 ASH Scholar Award Study Section (Member)
 2016 - 2018 Patient Centered Outcomes Research Initiative, CIBMTR (Member)
 2017 - Present ASBMT HCT Value and Health Economics SIG (Member)
 2017 - Present EPIC BMT Module Design Group (Member)
 2017 - 2018 ASH Awards Review Subcommittee (Member)
 2017 - 2018 CIBMTR EMR User Group (Member)
 2018 - Present CAR-T Slide Library Development Working Group (Member)
 2018 - 2023 Ohio Hematopoietic Stem Cell Transplant Consortium Board of Trustees (Member)
 2018 - 2019 ASBMT Quality Outcomes Committee (Vice-chair)
 2018 - 2019 ASBMT/CIBMTR Task Force for Center Outcomes Analysis (Member)
 2018 - Present ASBMT Informatics Subcommittee (Member)
 2018 - Present ASBMT Survivorship SIG (Member)
 2018 - 2022 EPIC Hematology Steering Committee (Member)
 2019 - Present NMDP IRB (Member)
 2019 - 2021 ASH Quality Measures Oversight Committee (Member)
 2019 - 2022 ASTCT Quality Outcomes Committee (Chair)
 2019 - 2022 Association of American Cancer Institutes CAR-T Clinical Best Practice Working Group (Member)
 2019 - 2022 Beacon Operational Community Group (Member)
 2019 - Present Healthcare Information and Management Systems Society (Member)
 2019 - Present ASH Reimbursement Subcommittee (Member)
 2019 - Present American Medical Informatics Association (Member)
 2020 ASH HONORS Study Section (Member)
 2020 - 2023 Transplant-Associated Learning Network Team (TALNT) Leadership Team (Founding Member)
 2020 - 2022 FACT Clinical Outcomes Improvement Committee (Ex officio member)
 2020 - 2024 ASTCT Finance Committee (Member)
 2021 ASH HONORS Study Section (Member)
 2021 ASH Supplemental Award Study Section (Member)
 2021 - 2023 NMDP Barriers to Access Advisory Board (Member)
 2022 - Present ASTCT Quality Outcomes Committee (Ex officio member)
 2022 - Present ASTCT Value and Health Economics Steering SIG Committee (Member)
 2023 - Present NMDP ACCESS Awareness Committee (Member)
 2024 - Present ENGRAFT Community Engagement Committee (Co-chair)
 2024 - Present ASTCT Journal Editorial Board (Member)

EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS:

Journal Review

Biology of Blood and Marrow Transplantation, Journal of Comparative Effectiveness Research, Bone Marrow Transplantation, JAMA Oncology, American Journal of Hematology
 Leukemia, Expert Reviews in Anticancer Therapy, Expert Review of Hematology, Blood, Haematologica, Future Medicine New England Journal of Medicine, Future Oncology

RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS:

Active

Peer Review

Title:

RFA: PA-20-183: Chlorhexidine
 Bathing on Bloodstream Infection Rates
 after Stem Cell Transplantation

Source:

NIH (Submitted 10/2020, not funded,
 planned resubmission)

Role & Effort: Co-Investigator (10%)
Dates: 07/07/2021 - 06/20/2026
Direct Funds: \$435,111 (Sponsor: Cincinnati Children's Hospital)

Pending

Peer Review

Title: OSU 12207: Project Buck-i-Pad: The evaluation of an iPad distribution program on anxiety and depression in blood and marrow transplant patients

Role & Effort: PI
PI: Jaglowski, Samantha
Dates: 2012 - 2015

Title: RDCRN-6502: A randomized phase II study of imatinib and rituximab for cutaneous sclerosis after allogeneic hematopoietic cell transplantation
Source: Fred Hutchinson Cancer Research Center

Role & Effort: Institutional principle investigator
Dates: 2013 - 2014

Title: BMT CTN 0801: A phase II/III randomized, multicenter trial comparing sirolimus plus prednisone and sirolimus/calcineurin inhibitor plus prednisone for the treatment of chronic graft-versus-host disease

Source: Blood and Marrow Transplant Clinical Trials Network

Role & Effort: Institutional principle investigator
Dates: 2013

Non-Peer Review

Title: OSU 12162: A Phase I Study of Milatuzumab (hLL1) for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies

Source: Immunomedics, Inc.
Dates: 09/18/2013 - 09/18/2015
Direct Funds: \$228,954

Prior

Peer Review

Title: OSU 10053: A phase Ib/II study of PCI-32765, a Btk-inhibitor, and ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and related diseases.

Role & Effort:	PI
PI:	Jagowski, Samantha
Dates:	2010 - 2013
Title:	A phase Ib/II study of PCI-32765, a Btk-inhibitor, and ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and related diseases
Source:	American Society of Hematology Scholar Award
Role & Effort:	PI
PI:	Jagowski, Samantha
Dates:	07/01/2011 - 06/30/2013
Direct Funds:	\$100,000
Title:	A phase Ib/II study of PCI-32765, a Btk-inhibitor, and ofatumumab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma and related diseases
Source:	ASCO Young Investigator Award
Role & Effort:	PI
PI:	Jagowski, Samantha
Dates:	07/01/2011 - 06/30/2012
Direct Funds:	\$50,000
Title:	OSU 11163: A pilot study of lenalidomide maintenance therapy following autologous stem cell transplantation in patients with relapsed/refractory Hodgkin lymphoma
Source:	Washington University School of Medicine
Role & Effort:	Institutional principle investigator
Dates:	2011 - 2015
Title:	A Phase I study of Milatuzumab (hLL1) for Prevention of Acute Graft versus Host Disease following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant
Source:	K12 CA133250-03 Translational Training Grant in Experimental Therapeutics
Role & Effort:	Scholar
Dates:	08/01/2012 - 07/31/2015
Direct Funds:	\$130,000 (\$100,000/year salary support and \$30,000/year research support)
Title:	OSU 12162: A phase I study of milatuzumab (hLL1) for prevention of acute graft-versus-host disease following reduced-intensity conditioning allogeneic stem cell transplant in patients

Source:	with hematologic malignancies Immunomedics
Role & Effort:	PI
PI:	Jaglowski, Samantha
Dates:	2012 - 2015
Title:	A Phase I Study of Milatuzumab for Prevention of Acute Graft versus Host Disease
Source:	American Society of Blood and Marrow Transplant New Investigator Award
Role & Effort:	PI
PI:	Jaglowski, Samantha
Dates:	07/01/2013 - 06/30/2015
Direct Funds:	\$25,000
Title:	OSU 13135: Comprehensive Frailty Assessment
Role & Effort:	PI
PI:	Jaglowski, Samantha
Dates:	2013 - 2015
Title:	OSU 14224: Chronic GVHD Response Measures Validation
Source:	National Institutes of Health
Role & Effort:	Institutional principle investigator
Dates:	2014 - 2016
Title:	OSU 14094: A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft- versus-host disease
Source:	Pharmacyclics, Inc.
Role & Effort:	Co-protocol director
Dates:	2014 - 2017
Title:	OSU 14233: Randomized study of individualized care plans for hematopoietic cell transplant survivors
Role & Effort:	Institutional principle investigator
PI:	National Marrow Donor Program
Dates:	2014 - 2016
Title:	OSU 14212: A phase II, single arm, multicenter trial to determine the efficacy and safety of CTL019 in adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)
Source:	Novartis
Role & Effort:	Institutional principle investigator
Dates:	2014 - 2017
Title:	OSU 14079: A pilot study of CDX-301 (rhuFlt3L) with or without Plerixafor for the mobilization and transplantation of allogeneic blood cell grafts in HLA- matched donor/recipient sibling pairs

Source:	Celldex Therapeutics
Role & Effort:	Institutional principle investigator
Dates:	2014 - 2016
Title:	OSU 15285: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy in Subjects with Chronic Graft Versus Host Disease (cGVHD)
Source:	Gilead Sciences
Dates:	2015 - 2017
Title:	OSU 15129: An international phase 2 open-label efficacy and safety study of MDV9300 in patients with an incomplete response following salvage therapy or autologous stem cell transplantation for relapsed or refractory CD20+ diffuse large B cell lymphoma
Source:	Medivation
Dates:	2015 - 2017
Title:	OSU 15286: A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus-Host Disease Following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
Source:	OncoImmune
Dates:	2015 - 2023
Title:	OSU 15254: Phase 1/2 Study of Autologous T Lymphocytes with Antibody-Dependent Cellular Cytotoxicity in Subjects with Relapsed or Refractory CD20-Positive B-cell Lymphoma
Source:	Unum Therapeutics
Dates:	2015 - 2023
Title:	OSU 15279: Carfilzomib for treatment of chronic graft vs. host disease
Source:	Fred Hutchinson Cancer Research Center
Dates:	2015 - 2017
Title:	OSU 16135: Long-term Follow-up Study of Clinical Study Subjects Treated with ACTR087, Autologous T Cells Expressing Antibody-Coupled T cell Receptors
Source:	Unum Therapeutics
Dates:	2016 - 2023
Title:	OSU 17092: A Pilot Study of

	Atezolizumab (MPDL3280A) Following Adoptive Cell Transfer in Active Hematologic or Solid Tumor Malignancies
Source:	National Cancer Institute
Dates:	2017 - 2023
Title:	OSU 17130: A Multicenter, Open-Label, Expanded Access Study of Axicabtagene Ciloleucel for the Treatment of Subjects with Relapsed/Refractory Large B-Cell Lymphoma
Source:	Kite Therapeutics
Dates:	2017 - 2023
Title:	OSU 17007: A Phase II Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects with Relapsed/Refractory Mantle Cell Lymphoma
Source:	Kite Therapeutics
Dates:	2017 - 2023
Title:	OSU 17244: A Phase III Randomized Open-Label, Multicenter Study of Ruxolitinib vs. Best Available Therapy in Patients with Corticosteroid-Refractory Chronic Graft vs Host Disease after Allogeneic Stem Cell Transplantation (REACH 3)
Source:	Incyte
Dates:	2017 - 2019
Title:	OSU 17326: A Phase III, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel versus Standard of Care Therapy in Subjects with Relapsed/Refractory Diffuse Large B Cell Lymphoma (ZUMA 7)
Source:	Kite Therapeutics
Dates:	2017 - 2023
Title:	OSU 17235: A Phase 1b/2 Open-Label Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 592 in Adult Subjects with Steroid Refractory Chronic Graft-versus-Host Disease
Source:	Amgen
Dates:	2017 - 2023
Title:	OSU 17170: A Phase 1 Study of ACTR707, an Autologous T Cell Product, in Combination with Rituximab, in Subjects with Relapsed or

Source:	Refractory CD20+ B Cell Lymphoma
Dates:	Unum Therapeutics 2017 - 2023
Title:	OSU 18222: Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
Source:	Novartis
Dates:	2018 - 2023
Title:	OSU 18223: A Phase Ib, Multicenter Study to Determine the Safety and Tolerability of Tisagenlecleucel in Combination with Ibrutinib in Adult Patients with Relapsed and/or Refractory Diffuse Large B Cell Lymphoma
Source:	Novartis
Dates:	2018 - 2023
Title:	OSU 18224: Managed Access Program (MAP) to Provide Access to CTL019 for Acute Lymphoblastic Leukemia (ALL) or Diffuse Large B Cell Lymphoma (DLBCL) Patients with Out of Specification Leukapheresis Product and/or Manufactured Tisagenlecleucel out of Specification for Commercial Release
Source:	Novartis
Dates:	2018 - 2023
Title:	OSU 20245: Expanded Access Protocol (EAP) for Patients Receiving Lisocabtagene Maraleucel that is Nonconforming for Commercial Release
Source:	Juno Therapeutics
Dates:	2020 - 2023
Title:	OSU 20305: Transplant Associated Learning Network Team (TALNT) to Improve the Health of Pediatric and Adult Stem Cell Transplant Recipients - TALNT Umbrella Protocol
Source:	Cincinnati Children's Hospital
Dates:	2020 - 2023

Non-Peer Review

Title:	OSU 10053: A Phase Ib/II Study of PCI-32765, a BTK-inhibitor, and Ofatumumab in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Related Diseases
Source:	Pharmacyclics, Inc.

Dates:	01/07/2011 - 12/31/2015
Direct Funds:	\$820,824
Title:	OSU 11163: A Pilot Study of Lenalidomide Maintenance Therapy Following Autologous Stem Cell Transplantation in Patients with Relapsed/Refractory Hodgkin Lymphoma
Source:	Washington University
Dates:	06/10/2012 - 06/10/2017
Direct Funds:	\$188,448
Title:	OSU 14094: A Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid Dependent or Refractory Chronic Graft vs Host Disease
Source:	Pharmacyclics Inc.
Dates:	09/08/2014 - 12/27/2016
Direct Funds:	\$598,007
Title:	OSU 14079: A Pilot Study of CDX-301 (rhuFlt3L) With or Without Plerixafor for the Mobilization and Transplantation of Allogeneic Blood Cell Grafts in HLA-Matched Donor/Recipient Sibling Pairs
Source:	Celldex Therapeutics, Inc.
Dates:	09/15/2014 - 09/15/2016
Direct Funds:	\$346,852
Title:	OSU 14233: A Randomized Study of Individualized Care Plans for Hematopoietic Cell Transplant Survivors
Source:	National Marrow Donor Program
Dates:	03/31/2015 - 03/31/2017
Direct Funds:	\$8,600
Title:	OSU 14212: A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Source:	Novartis Pharmaceuticals Corp
Dates:	10/30/2015 - 06/14/2022
Direct Funds:	\$480,922 ()
Title:	OSU 15285: A Phase 2, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination with Systemic Corticosteroids as First-Line Therapy
Source:	Gilead Sciences, Inc
Dates:	04/04/2016 - 04/04/2018
Direct Funds:	\$269,000
Title:	OSU 15279: Carfilzomib for Treatment

Source:	of Chronic Graft vs Host Disease Fred Hutchinson Cancer Research Center
Dates:	07/22/2016 - 07/22/2018
Direct Funds:	\$69,000
Title:	OSU 15254: Phase 1/2 Study of Autologous T Lymphocytes with Antibody-Dependent Cellular Cytotoxicity in Subjects with Relapsed or Refractory CD20-positive B-cell Lymphoma
Source:	Unum Therapeutics
Dates:	09/16/2016 - 09/06/2018
Direct Funds:	\$854,094
Title:	OSU 15286: A Phase II Trial of CD24Fc for Prevention of Acute Graft-versus- Host Disease following Myeloablative Allogeneic Hematopoietic Stem Cell Transplant
Source:	University of Michigan
Dates:	11/29/2016 - 08/03/2021
Direct Funds:	\$227,690

INVITED LECTURES/WORKSHOPS/PRESENTATIONS:

International

The Next Frontier of Cancer Treatment: Adoptive Cellular Therapies, Patient Education Event, Toronto, ON,
05/09/2019

National

Project Cancer Education, Oral Presentation, Arthur G. James Cancer Hospital, Columbus, OH, 10/07/2009
Lovenox Hurts, Podcast, Annals of Internal Medicine, 10/20/2009
Project Cancer Education, Oral Presentation, Arthur G. James Cancer Hospital, Columbus, OH, 01/08/2010
Project Cancer Education, Oral Presentation, Arthur G. James Cancer Hospital, Columbus, OH, 01/28/2010
Salvage Regimens with Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab
Era: the CORAL Study, BMT Journal Club, The Ohio State University, Columbus, OH, 05/05/2011
Project Cancer Education, Oral Presentation, Arthur G. James Cancer Hospital, Columbus, OH, 10/28/2011
Late Effects of Hematopoietic Stem Cell Transplant, Internal Medicine Grand Rounds, The Ohio State
University, Columbus, OH, 12/01/2011
Aggressive Lymphomas, BMT Continuing Nursing Education, The Ohio State University, Columbus, OH,
02/22/2012
Project Cancer Education, Oral Presentation, Arthur G. James Cancer Hospital, Columbus, OH, 02/22/2012
Non-Hodgkin's Lymphoma, Sanofi Education Session, The Ohio State University, Columbus, OH,
11/12/2013
Ask the Expert: Bone Marrow Transplant, JamesCare Survivorship, Columbus, OH, 12/14/2013
A Phase Ib/II Multi-Center Study of Ibrutinib in Steroid Dependent/Refractory Chronic Graft-versus-Host
Disease, Pharmacyclics Advisory Board, Grapevine, TX, 02/25/2014
Stem Cell Transplantation, Fellows' Board Review, The Ohio State University, Columbus, OH, 08/22/2014
Graft-versus-Host Disease, Dermatology Residents' Didactic, The Ohio State University, Columbus, OH,
09/03/2014
Stem Cell Transplantation for the General Internist, Internal Medicine Residents' Didactic, The Ohio State
University, Columbus, OH, 06/09/2015
GVHD and Rehabilitation Implications, Keynote address, Oncology Rehabilitation Conference, The Ohio
State University, Columbus, OH, 04/01/2017
Long-Term Care Clinic, Hematology and Transplant Clinic Continuing Education Series, The Ohio State

University, Columbus, OH, 06/14/2017 - 06/14/2014

Adoptive Cellular Therapy for the Emergency Provider, James/ED Case Conference, The Ohio State University, Columbus, OH, 06/15/2017

The Next Frontier of Cancer Treatment: Adoptive Cellular Therapies, Cell Therapy Grand Rounds, The Ohio State University, Columbus, OH, 08/30/2017

Adoptive Cellular Therapy: Potential Pitfalls, Heme/Onc Fellow Lecture, The Ohio State University, Columbus, OH, 10/31/2017

Adoptive Cellular Therapy, The Zangmeister Center, Columbus, OH, 12/01/2017

Adoptive Cellular Therapy, Heme/Onc Grand Rounds, Edwards Cancer Center, Huntington, WV, 01/12/2018

Adoptive Cellular Therapy, ASH Review Keynote Lecture, The Ohio State University, Columbus, OH, 01/19/2018

Adoptive Cellular Therapy, Translational Research in Heme/Onc/BMT Series, Nationwide Children's Hospital, Columbus, OH, 03/23/2018

The Next Frontier of Cancer Treatment: Adoptive Cellular Therapies, BGSP 8800.00 Lecture, The Ohio State University, Columbus, OH, 04/17/2018

The Next Frontier of Cancer Treatment: Adoptive Cellular Therapies, APP Fellow Lecture, The Ohio State University, Columbus, OH, 06/28/2018

New Directions in the Management of Graft-Versus-Host Disease, Heme/Onc Grand Rounds, Edwards Cancer Center, Huntington, WV, 08/10/2018

The Next Frontier of Cancer Treatment: Adoptive Cellular Therapies, OhioHealth Congregational Partnership, Bing Cancer Center, Columbus, OH, 11/26/2018

Management of Adoptive Cellular Therapy Patients, Combined Neurocritical Care and Neurology Grand Rounds, The Ohio State University, Columbus, OH, 03/12/2019

The Next Frontier of Cancer Treatment: Adoptive Cellular Therapies, BGSP 8800.00 Lecture, The Ohio State University, Columbus, OH, 04/16/2019

Novartis CAR-T Meet the Expert Series: DLBCL: Grading scales and management algorithms for CAR-T cell therapy-associated CRS / NE in adult patients with DLBCL, Virtual meeting, Adobe Connect, 11/07/2019

Ask the Expert: CAR-T Cell Therapy, Virtual meeting via Zoom, JamesCare for Life, 09/24/2020

How COVID-19 Changed Telehealth: an Oncologist's Perspective, Virtual meeting, CSO HIMSS, 10/30/2020

Utilizing a Comprehensive Team-based Approach to Improving Patient-important Outcomes After Transplant, Session moderator, Transplant and Cellular Therapy Annual Meeting, Virtual meeting, 02/04/2021

Administrative Quality Session, Session moderator, Transplant and Cellular Therapy Annual Meeting, Virtual meeting, 02/09/2021

Hematology Update, Ohio State's 2022 ASCO Review, Columbus, OH, 06/09/2022

COMMITTEE SERVICE:

Hospital

2009 - 2011 Member, Project Cancer Education Internal Advisory Board, The Arthur G. James Cancer Hospital

2009 - 2010 Member, Adolescent and Young Adult Oncology Program Committee, The Arthur G. James Cancer Hospital

2010 Member, Fellowship Selection Committee, The Ohio State University Division of Hematology and Oncology, The Arthur G. James Cancer Hospital

2010 - 2012 Member, Blood and Marrow Transplant Survivorship Task Force, The Arthur G. James Cancer Hospital

2011 - 2012 Member, OSUMC Formulary Subcommittee, Oklahoma State University Medical Center

2011 - 2017 Member, BMT Program Clinical Quality Management Committee, The Arthur G. James Cancer Hospital

2011 - 2012 Member, OSUMC Pharmacy and Therapeutics Executive Committee, Oklahoma State University Medical Center

2013 - 2016 Member, Graft-versus-Host Disease Grading Committee, The Arthur G. James Cancer Hospital

2015 - 2023 Member, Infection Prevention and Control Committee, The Ohio State University Wexner

Medical Center

2016 - 2017 Member, Adolescent and Young Adult Clinical Care Subcommittee, The Arthur G. James Cancer Hospital and Nationwide Children's Hospital

2016 - 2017 Co-chair, Adolescent and Young Adult Research Subcommittee, The Arthur G. James Cancer Hospital and Nationwide Children's Hospital

2016 - 2018 Member, Biomedical Institutional Review Board, The Ohio State University Wexner Medical Center

2016 - 2023 Member, Hematology Operations Leadership Committee, The Ohio State University Wexner Medical Center

2016 - 2021 Chair, BMT Program Meeting, The Arthur G. James Cancer Hospital

2017 - 2023 Member, IHIS Decision Support Committee, The Ohio State University Wexner Medical Center

2017 - 2023 Chair, BMT Program Clinical Quality Management Committee, The Arthur G. James Cancer Hospital

2017 - 2021 Member, Patient Experience Council, The Arthur G. James Cancer Hospital

2017 - 2023 Member, Health Systems IT Steering Committee, The Ohio State University Wexner Medical Center

2017 - 2018 Member, Adolescent and Young Adult Advisory Council, The Arthur G. James Cancer Hospital

2017 - 2023 Chair, James Cell Therapy Quality Workgroup, The Arthur G. James Cancer Hospital

2017 - 2023 Co-chair, Oncology Stakeholder Group, The Arthur G. James Cancer Hospital

2017 - 2023 Member, Medical Documentation Steering Committee, The Ohio State University Wexner Medical Center

2017 - 2023 Member, IHIS Physician Advisory Committee, The Ohio State University Wexner Medical Center

2018 - 2021 Member, Antibiotics Stewardship Committee, The Ohio State University Wexner Medical Center

2019 - 2023 Member, Healthwise Patient Education Implementation Oversight Committee, The Ohio State University Wexner Medical Center

2020 - 2022 Member, Hematology: Offices West Campus Ambulatory Building User Group, The Arthur G. James Cancer Hospital

2020 - 2022 Member, Hematology: Clinic West Campus Ambulatory Building User Group, The Arthur G. James Cancer Hospital

2020 - 2021 Member, Telehealth: Transitions of Care and Chronic Condition Management, The Ohio State University Wexner Medical Center

2020 - 2022 Member, Outreach Telehealth Subcommittee, The Ohio State University Wexner Medical Center

2020 - 2021 Member, Second Chemo Episode Type Committee, The Arthur G. James Cancer Hospital

2020 - 2021 Member, COVID-19 Telehealth Subgroup, The Ohio State University Wexner Medical Center

2021 - 2022 Member, Scribe/Workflow Subcommittee, The Arthur G. James Cancer Hospital

2021 - 2023 Member, Physician/Executive IT Committee, The Ohio State University Wexner Medical Center

2021 - 2023 Member, Utilization Review Committee, The Arthur G. James Cancer Hospital

2021 - 2022 Member, Telehealth User Group, The Ohio State University Wexner Medical Center

2022 Co-Chair, Patient Care and Research Subcommittee, James Diversity, Equity, and Inclusion Committee, The Arthur G. James Cancer Hospital

EXTRAMURAL TEACHING:

Medical Student Education

2011 - 2012 The Ohio State University College of Medicine and Public Health, Columbus, OH, Clinical Assessment and Problem Solving," Preceptor for a first-year medical student

2012 - 2013 The Ohio State University College of Medicine and Public Health, Columbus, OH, Preceptor for Med4 students and internal medicine residents on outpatient hematology/oncology elective

EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS

MENTORED:

Medical Students

- 2019 - 2022 Amneet Bajwa, MD, MBA, Internal Medicine Resident, The Ohio State University College of Medicine and Public Health, Columbus, OH
- 2022 - 2023 Brandon Rodgers, 4th-Year Medical Student, Mentor, The Ohio State University College of Medicine and Public Health, Columbus, OH

Clinical/Research Fellows

- 2013 - 2015 Brad Haverkos, MD, MPH, Heme/Onc Fellow, Mentor, The Ohio State University College of Medicine and Public Health, Columbus, OH
- 2014 - 2016 Marcello Rotta, MD, Heme/Onc Fellow, Mentor, The Ohio State University College of Medicine and Public Health, Columbus, OH
- 2016 - 2019 Joseph Maakaron, MD, Heme/Onc Fellow, Mentor, The Ohio State University College of Medicine and Public Health, Columbus, OH
- 2016 - 2023 Polina Shindiapina, MD, PhD, Heme/Onc Fellow, Mentor, The Ohio State University College of Medicine and Public Health, Columbus, OH
- 2017 - Present Nathan Denlinger, MD, Heme/Onc Fellow, Mentor, The Ohio State University College of Medicine and Public Health, Columbus, OH
- 2019 - 2022 Audrey Sigmund, MD, Heme/Onc Fellow, Mentor, The Ohio State University College of Medicine and Public Health, Columbus, OH
- 2022 - 2023 Harshil Bhatt, MBBS, Bone Marrow Transplant Fellow, Mentor, The Ohio State University College of Medicine and Public Health, Columbus, OH

BIBLIOGRAPHY

Refereed Journal Publications/Original Papers

1. Jaglowski SM, Linden E, Termuhlen AM, Flynn JM. Lymphoma in adolescents and young adults. *Semin Oncol.* 2009 Oct;36(5):381-418.
2. Jaglowski SM, Geyer SM, Heerema NA, Elder P, Scholl D, Byrd JC, Devine SM, Andritsos LA. Barriers to Proceeding to Reduced-Intensity Allogeneic Stem Cell Transplant in Chronic Lymphocytic Leukemia. *J Leuk.* 2013; 1:121.
3. Jaglowski SM, de Lima M. EXABS-211-CT Building Your CAR-T Program. *Clin Lymphoma Myeloma Leuk.* 2022 Oct;22 Suppl 2:S104-S105. PMID: 36163705.
4. Jaglowski SM. Lovenox hurts. *Ann Intern Med.* 2009 Oct 20;151(8):585-6.
5. Jaglowski SM, Byrd JC. Rituximab in chronic lymphocytic leukemia. *Semin Hematol.* 2010 Apr;47(2):156-69.
6. Jaglowski SM, Alinari L, Lapalombella R, Muthusamy N, Byrd JC. The clinical application of monoclonal antibodies in chronic lymphocytic leukemia. *Blood.* 2010 Nov 11;116(19):3705-14. PMID: PMC2981531
7. Herman SE, Gordon AL, Hertlein E, Ramanunni A, Zhang X, Jaglowski S, Flynn J, Jones J, Blum KA, Buggy JJ, Hamdy A, Johnson AJ, Byrd JC. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765. *Blood.* 2011 Jun 09;117(23):6287-96. PMID: PMC3122947
8. Jaglowski S, Jones JA. Choosing first-line therapy for chronic lymphocytic leukemia. *Expert Rev Anticancer Ther.* 2011 Sep;11(9):1379-90. PMID: PMC4341916
9. Jaglowski SM, Byrd JC. Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia. *Biol Blood Marrow Transplant.* 2012 Jan;18(1 Suppl):S132-8.
10. Jaglowski SM, Ruppert AS, Heerema NA, Bingman A, Flynn JM, Grever MR, Jones JA, Elder P, Devine SM, Byrd JC, Andritsos LA. Complex karyotype predicts for inferior outcomes following reduced-intensity conditioning allogeneic transplant for chronic lymphocytic leukaemia. *Br J Haematol.* 2012 Oct;159(1):82-7. PMID: PMC3719859
11. Dubovsky JA, Beckwith KA, Natarajan G, Woyach JA, Jaglowski S, Zhong Y, Hessler JD, Liu TM, Chang BY, Larkin KM, Stefanovski MR, Chappell DL, Frizzera FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman AM, Furman R, Sharman J, Mishra A, Caligiuri MA, Satoskar AR, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. *Blood.* 2013 Oct

- 10;122(15):2539-49. PMID: PMC3795457
12. Stephens DM, Ruppert AS, Jones JA, Woyach J, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Johnson AJ, Muthusamy N, Heerema NA, Byrd JC. Impact of targeted therapy on outcome of chronic lymphocytic leukemia patients with relapsed del(17p13.1) karyotype at a single center. *Leukemia*. 2014 Jun;28(6):1365-8. PMID: PMC4047185
 13. Jaglowski SM, Devine SM. Graft-versus-host disease: why have we not made more progress? *Curr Opin Hematol*. 2014 Mar;21(2):141-7. PMID: PMC4131840
 14. Haverkos BM, McBride A, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos LA, Devine SM, Jaglowski SM. An effective mobilization strategy for lymphoma patients after failed upfront mobilization with plerixafor. *Bone Marrow Transplant*. 2014 Aug;49(8):1052-5. PMID: PMC4125480
 15. El-Jawahri A, Pidala J, Inamoto Y, Chai X, Khera N, Wood WA, Cutler C, Arora M, Carpenter PA, Palmer J, Flowers M, Weisdorf D, Pavletic S, Jaglowski S, Jagasia M, Lee SJ, Chen YB. Impact of age on quality of life, functional status, and survival in patients with chronic graft-versus-host disease. *Biol Blood Marrow Transplant*. 2014 Sep;20(9):1341-8. PMID: PMC4127362
 16. Bechtel T, McBride A, Crawford B, Bullington S, Hofmeister CC, Benson DM Jr, Jaglowski S, Penza S, Andritsos LA, Devine SM. Aprepitant for the control of delayed nausea and vomiting associated with the use of high-dose melphalan for autologous peripheral blood stem cell transplants in patients with multiple myeloma: a phase II study. *Support Care Cancer*. 2014 Nov;22(11):2911-6.
 17. Woyach JA, Furman RR, Liu TM, Ozer HG, Zapatka M, Ruppert AS, Xue L, Li DH, Steggerda SM, Versele M, Dave SS, Zhang J, Yilmaz AS, Jaglowski SM, Blum KA, Lozanski A, Lozanski G, James DF, Barrientos JC, Lichter P, Stilgenbauer S, Buggy JJ, Chang BY, Johnson AJ, Byrd JC. Resistance mechanisms for the Bruton's tyrosine kinase inhibitor ibrutinib. *N Engl J Med*. 2014 Jun 12;370(24):2286-94. PMID: PMC4144824
 18. Jaglowski SM, Ruppert AS, Hofmeister CC, Elder P, Blum W, Klisovic R, Vasu S, Penza S, Efebera YA, Benson DM Jr, Devine SM, Andritsos LA. The hematopoietic stem cell transplant comorbidity index can predict for 30-day readmission following autologous stem cell transplant for lymphoma and multiple myeloma. *Bone Marrow Transplant*. 2014 Oct;49(10):1323-9. PMID: PMC4192086
 19. Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos L, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera YA. Lower dose of antithymocyte globulin does not increase graft-versus-host disease in patients undergoing reduced-intensity conditioning allogeneic hematopoietic stem cell transplant. *Leuk Lymphoma*. 2015 Apr;56(4):1058-65. PMID: PMC4417073
 20. Hofmeister CC, Williams N, Geyer S, Hade EM, Bowers MA, Earl CT, Vaughn J, Bingman A, Humphries K, Lozanski G, Baiocchi RA, Jaglowski SM, Blum K, Porcu P, Flynn J, Penza S, Benson DM, Andritsos LA, Devine SM. A phase 1 study of vorinostat maintenance after autologous transplant in high-risk lymphoma. *Leuk Lymphoma*. 2015 Apr;56(4):1043-9. PMID: PMC4417026
 21. Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B, Yang C, Towns WH, Lehman A, Johnson AJ, Muthusamy N, Devine SM, Jaglowski S, Serody JS, Murphy WJ, Munn DH, Luznik L, Hill GR, Wong HK, MacDonald KK, Maillard I, Koreth J, Elias L, Cutler C, Soiffer RJ, Antin JH, Ritz J, Panoskaltis-Mortari A, Byrd JC, Blazar BR. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. *J Clin Invest*. 2014 Nov;124(11):4867-76. PMID: PMC4347242
 22. Maddocks K, Christian B, Jaglowski S, Flynn J, Jones JA, Porcu P, Wei L, Jenkins C, Lozanski G, Byrd JC, Blum KA. A phase 1/1b study of rituximab, bendamustine, and ibrutinib in patients with untreated and relapsed/refractory non-Hodgkin lymphoma. *Blood*. 2015 Jan 08;125(2):242-8.
 23. Amin EN, Phillips GS, Elder P, Jaglowski S, Devine SM, Wood KL. Health-related quality of life in patients who develop bronchiolitis obliterans syndrome following allo-SCT. *Bone Marrow Transplant*. 2015 Feb;50(2):289-95. PMID: PMC4351778
 24. Guinn D, Ruppert AS, Maddocks K, Jaglowski S, Gordon A, Lin TS, Larson R, Marcucci G, Hertlein E, Woyach J, Johnson AJ, Byrd JC. miR-155 expression is associated with chemioimmunotherapy outcome and is modulated by Bruton's tyrosine kinase inhibition with Ibrutinib. *Leukemia*. 2015 May;29(5):1210-3. PMID: PMC4424166
 25. Jaglowski SM. Transplant for CLL: still an option? *Blood*. 2014 Dec 18;124(26):3835-6.
 26. Flynn J, Jones J, Johnson AJ, Andritsos L, Maddocks K, Jaglowski S, Hessler J, Grever MR, Im E, Zhou H, Zhu Y, Zhang D, Small K, Bannerji R, Byrd JC. Dinaciclib is a novel cyclin-dependent kinase inhibitor with significant clinical activity in relapsed and refractory chronic lymphocytic leukemia. *Leukemia*. 2015 Jul;29(7):1524-9. PMID: PMC4551390
 27. Liu TM, Woyach JA, Zhong Y, Lozanski A, Lozanski G, Dong S, Strattan E, Lehman A, Zhang X, Jones JA,

- Flynn J, Andritsos LA, Maddocks K, Jaglowski SM, Blum KA, Byrd JC, Dubovsky JA, Johnson AJ. Hypermorphic mutation of phospholipase C, ?2 acquired in ibrutinib-resistant CLL confers BTK independency upon B-cell receptor activation. *Blood*. 2015 Jul 02;126(1):61-8. PMID: PMC4492196
28. Bachanova V, Burns LJ, Ahn KW, Laport GG, Akpek G, Kharfan-Dabaja MA, Nishihori T, Agura E, Armand P, Jaglowski SM, Cairo MS, Cashen AF, Cohen JB, D'Souza A, Freytes CO, Gale RP, Ganguly S, Ghosh N, Holmberg LA, Inwards DJ, Kanate AS, Lazarus HM, Malone AK, Munker R, Mussetti A, Norkin M, Prestidge TD, Rowe JM, Satwani P, Siddiqi T, Stiff PJ, William BM, Wirk B, Maloney DG, Smith SM, Sureda AM, Carreras J, Hamadani M, Center for International Blood and Marrow Transplant Research Lymphoma Working Committee. Impact of Pretransplantation (18)F-fluorodeoxy Glucose-Positron Emission Tomography Status on Outcomes after Allogeneic Hematopoietic Cell Transplantation for Non-Hodgkin Lymphoma. *Biol Blood Marrow Transplant*. 2015 Sep;21(9):1605-11. PMID: PMC4558181
29. Jaglowski SM, Jones JA, Nagar V, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Smucker K, Ruppert AS, Heerema NA, Lozanski G, Stefanos M, Munneke B, West JS, Neuenburg JK, James DF, Hall N, Johnson AJ, Byrd JC. Safety and activity of BTK inhibitor ibrutinib combined with ofatumumab in chronic lymphocytic leukemia: a phase 1b/2 study. *Blood*. 2015 Aug 13;126(7):842-50. PMID: PMC4536539
30. Roddy JV, Haverkos BM, McBride A, Leininger KM, Jaglowski S, Penza S, Klisovic R, Blum W, Vasu S, Hofmeister CC, Benson DM, Andritsos LA, Devine SM, Efebera YA. Tocilizumab for steroid refractory acute graft-versus-host disease. *Leuk Lymphoma*. 2016;57(1):81-5. PMID: PMC4698359
31. Maddocks KJ, Ruppert AS, Lozanski G, Heerema NA, Zhao W, Abruzzo L, Lozanski A, Davis M, Gordon A, Smith LL, Mantel R, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Woyach JA. Etiology of Ibrutinib Therapy Discontinuation and Outcomes in Patients With Chronic Lymphocytic Leukemia. *JAMA Oncol*. 2015 Apr;1(1):80-7. PMID: PMC4520535
32. Stephens DM, Ruppert AS, Weirda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam C, O'Brien S, Keating MJ, Muthusamy N, Abruzzo LV, Heerema NA, Byrd JC. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. *Am J Hematol*. 2015 Nov;90(11):967-9. PMID: PMC7055503
33. Efebera YA, Geyer S, Andritsos L, Vasu S, Jaglowski S, Bingman A, Blum W, Klisovic R, Hofmeister CC, Benson DM, Penza S, Elder P, Cortright K, Kitzler R, Coombes K, O'Donnell L, Daneault B, Bradbury H, Zhang J, Chen X, Garman S, Ranganathan P, Yu X, Hofstetter J, Yu J, Garzon R, Scrape SR, Lozanski G, Devine SM. Atorvastatin for the Prophylaxis of Acute Graft-versus-Host Disease in Patients Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation (allo-HCT). *Biol Blood Marrow Transplant*. 2016 Jan;22(1):71-9. PMID: PMC4706501
34. Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Khera N, Palmer J, Chen GL, Jagasia MH, Mayer SA, Wood WA, Green M, Hyun TS, Inamoto Y, Storer BE, Miklos DB, Shulman HM, Martin PJ, Sarantopoulos S, Lee SJ, Flowers ME. A Randomized Phase II Crossover Study of Imatinib or Rituximab for Cutaneous Sclerosis after Hematopoietic Cell Transplantation. *Clin Cancer Res*. 2016 Jan 15;22(2):319-27. PMID: PMC4715914
35. Rogers KA, Ruppert AS, Bingman A, Andritsos LA, Awan FT, Blum KA, Flynn JM, Jaglowski SM, Lozanski G, Maddocks KJ, Byrd JC, Woyach JA, Jones JA. Incidence and description of autoimmune cytopenias during treatment with ibrutinib for chronic lymphocytic leukemia. *Leukemia*. 2016 Feb;30(2):346-50. PMID: PMC4986508
36. Vasu S, Geyer S, Bingman A, Auletta JJ, Jaglowski S, Elder P, O'Donnell LC, Bradbury H, Kitzler R, Andritsos L, Blum W, Klisovic R, Penza S, Efebera Y, Hofmeister C, Benson DM, Muthusamy N, Lozanski G, Devine SM. Granulocyte Colony-Stimulating Factor-Mobilized Allografts Contain Activated Immune Cell Subsets Associated with Risk of Acute and Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2016 Apr;22(4):658-668.
37. Kaffenberger BH, Zhang E, Duncan JR, Jaglowski S, Klisovic RB, Devine SM, Wong HK, Gru AA. Endothelial chimerism in chronic sclerotic-type chronic graft-versus-host disease (GVHD) and GVHD-associated angiomatosis. *Br J Dermatol*. 2016 Oct;175(4):782-4.
38. Vela CM, McBride A, Jaglowski SM, Andritsos LA. Ibrutinib for treatment of chronic lymphocytic leukemia. *Am J Health Syst Pharm*. 2016 Mar 15;73(6):367-75.
39. Fenske TS, Ahn KW, Graff TM, DiGilio A, Bashir Q, Kamble RT, Ayala E, Bacher U, Brammer JE, Cairo

- M, Chen A, Chen YB, Chhabra S, D'Souza A, Farooq U, Freytes C, Ganguly S, Hertzberg M, Inwards D, Jaglowski S, Kharfan-Dabaja MA, Lazarus HM, Nathan S, Pawarode A, Perales MA, Reddy N, Seo S, Sureda A, Smith SM, Hamadani M. Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation. *Br J Haematol*. 2016 Jul;174(2):235-48. PMID: PMC4940282
40. Vasu S, Wu H, Satoskar A, Puto M, Roddy J, Blum W, Klisovic R, Andritsos L, Hofmeister C, Benson DM, Efebera Y, Jaglowski S, Penza S, Cohen D, Devine S, Cataland S. Eculizumab therapy in adults with allogeneic hematopoietic cell transplant-associated thrombotic microangiopathy. *Bone Marrow Transplant*. 2016 Sep;51(9):1241-4.
41. Ghosh N, Karmali R, Rocha V, Ahn KW, DiGilio A, Hari PN, Bachanova V, Bacher U, Dahi P, de Lima M, D'Souza A, Fenske TS, Ganguly S, Kharfan-Dabaja MA, Prestidge TD, Savani BN, Smith SM, Sureda AM, Waller EK, Jaglowski S, Herrera AF, Armand P, Salit RB, Wagner-Johnston ND, Fuchs E, Bolaños-Meade J, Hamadani M. Reduced-Intensity Transplantation for Lymphomas Using Haploidentical Related Donors Versus HLA-Matched Sibling Donors: A Center for International Blood and Marrow Transplant Research Analysis. *J Clin Oncol*. 2016 Sep 10;34(26):3141-9. PMID: PMC5012706
42. Ryan CE, Sahaf B, Logan AC, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJ, Mato AR, Keating MJ, Jaglowski S, Clow F, Rezvani AR, Styles L, Coutre SE, Miklos DB. Ibrutinib efficacy and tolerability in patients with relapsed chronic lymphocytic leukemia following allogeneic HCT. *Blood*. 2016 Dec 22;128(25):2899-2908. PMID: PMC5179333
43. Chen YB, Wang T, Hemmer MT, Brady C, Couriel DR, Alousi A, Pidala J, Urbano-Ispizua A, Choi SW, Nishihori T, Teshima T, Inamoto Y, Wirk B, Marks DI, Abdel-Azim H, Lehmann L, Yu L, Bitan M, Cairo MS, Qayed M, Salit R, Gale RP, Martino R, Jaglowski S, Bajel A, Savani B, Frangoul H, Lewis ID, Storek J, Askar M, Kharfan-Dabaja MA, Aljurf M, Ringden O, Reshef R, Olsson RF, Hashmi S, Seo S, Spitzer TR, MacMillan ML, Lazaryan A, Spellman SR, Arora M, Cutler CS. GvHD after umbilical cord blood transplantation for acute leukemia: an analysis of risk factors and effect on outcomes. *Bone Marrow Transplant*. 2017 Mar;52(3):400-408. PMID: PMC5332289
44. Haverkos BM, Huang Y, Elder P, O'Donnell L, Scholl D, Whittaker B, Vasu S, Penza S, Andritsos LA, Devine SM, Jaglowski SM. A single center's experience using four different front line mobilization strategies in lymphoma patients planned to undergo autologous hematopoietic cell transplantation. *Bone Marrow Transplant*. 2017 Apr;52(4):561-566. PMID: PMC5382040
45. Cohen JB, Maddocks KJ, Huang Y, Christian BA, Jaglowski SM, Flowers CR, Blum KA. A phase 2 trial of alisertib in patients with relapsed or refractory B-cell non-Hodgkin lymphoma. *Leuk Lymphoma*. 2017 Sep;58(9):1-2. PMID: PMC5497734
46. Guinn D, Lehman A, Fabian C, Yu L, Maddocks K, Andritsos LA, Jones JA, Flynn JM, Jaglowski SM, Woyach JA, Byrd JC, Johnson AJ. The regulation of tumor-suppressive microRNA, miR-126, in chronic lymphocytic leukemia. *Cancer Med*. 2017 Apr;6(4):778-787. PMID: PMC5387133
47. Woyach JA, Ruppert AS, Guinn D, Lehman A, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo L, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong TJ, Ny F, Lucas M, Chase W, Jones JA, Flynn JM, Maddocks K, Rogers K, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Lozanski G, Johnson AJ, Byrd JC. BTK^{C481S}-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia. *J Clin Oncol*. 2017 May 01;35(13):1437-1443. PMID: PMC5455463
48. Epperla N, Ahn KW, Ahmed S, Jagasia M, DiGilio A, Devine SM, Jaglowski S, Kennedy V, Rezvani AR, Smith SM, Sureda A, Fenske TS, Kharfan-Dabaja MA, Armand P, Hamadani M. Rituximab-containing reduced-intensity conditioning improves progression-free survival following allogeneic transplantation in B cell non-Hodgkin lymphoma. *J Hematol Oncol*. 2017 Jun 12;10(1):117. PMID: PMC5469142
49. Maly JJ, Christian BA, Zhu X, Wei L, Sexton JL, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston ND, Phelps MA, Bartlett NL, Blum KA. A Phase I/II Trial of Panobinostat in Combination With Lenalidomide in Patients With Relapsed or Refractory Hodgkin Lymphoma. *Clin Lymphoma Myeloma Leuk*. 2017 Jun;17(6):347-353. PMID: PMC6033275
50. Miklos D, Cutler CS, Arora M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Chang S, Lal I, Dubovsky J, James DF, Styles L, Jaglowski S. Ibrutinib for chronic graft-versus-host disease after failure of prior therapy. *Blood*. 2017 Nov 23;130(21):2243-2250. PMID: PMC6033048
51. Epperla N, Ahn KW, Armand P, Jaglowski S, Ahmed S, Kenkre VP, Savani B, Jagasia M, Shah NN, Fenske

- TS, Sureda A, Smith SM, Hamadani M. Fludarabine and Busulfan versus Fludarabine, Cyclophosphamide, and Rituximab as Reduced-Intensity Conditioning for Allogeneic Transplantation in Follicular Lymphoma. *Biol Blood Marrow Transplant*. 2018 Jan;24(1):78-85. PMID: PMC5743624
52. Myers RM, Hill BT, Shaw BE, Kim S, Millard HR, Battiwalla M, Majhail NS, Buchbinder D, Lazarus HM, Savani BN, Flowers MED, D'Souza A, Ehrhardt MJ, Langston A, Yared JA, Hayashi RJ, Daly A, Olsson RF, Inamoto Y, Malone AK, DeFilipp Z, Margossian SP, Warwick AB, Jaglowski S, Beitinjaneh A, Fung H, Kasow KA, Marks DI, Reynolds J, Stockerl-Goldstein K, Wirk B, Wood WA, Hamadani M, Satwani P. Long-term outcomes among 2-year survivors of autologous hematopoietic cell transplantation for Hodgkin and diffuse large b-cell lymphoma. *Cancer*. 2018 Feb 15;124(4):816-825. PMID: PMC5871233
53. Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenbach H, Lozanski G, Zhao W, Gordon AL, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Blum KA, T Awan F, Rogers KA, Grever MR, Johnson AJ, Abruzzo LV, Hertlein EK, Blachly JS, Woyach JA, Byrd JC. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. *Blood Adv*. 2017 Aug 22;1(19):1584-1588. PMID: PMC5728464
54. Jaglowski SM. Road trip to remission with CARs. *Blood*. 2017 Nov 23;130(21):2240.
55. Wiczter TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, Rogers K, McCoy A, Mousa L, Guha A, Heerema NA, Maddocks K, Christian B, Andritsos LA, Jaglowski S, Devine S, Baiocchi R, Woyach J, Jones J, Grever M, Blum KA, Byrd JC, Awan FT. Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib. *Blood Adv*. 2017 Sep 12;1(20):1739-1748. PMID: PMC5728342
56. Richardson DR, Huang Y, McGinty HL, Elder P, Newlin J, Kirkendall C, Andritsos L, Benson D, Blum W, Efebera Y, Penza S, Hofmeister C, Jaglowski S, Klisovic R, Vasu S, William B, Devine S, Rosko AE. Psychosocial risk predicts high readmission rates for hematopoietic cell transplant recipients. *Bone Marrow Transplant*. 2018 Nov;53(11):1418-1427. PMID: PMC6092254
57. O'Brien SM, Jaglowski S, Byrd JC, Bannerji R, Blum KA, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James DF, Chu AD, Coutre SE. Prognostic Factors for Complete Response to Ibrutinib in Patients With Chronic Lymphocytic Leukemia: A Pooled Analysis of 2 Clinical Trials. *JAMA Oncol*. 2018 May 01;4(5):712-716. PMID: PMC5885180
58. Rosko AE, Huang Y, Benson DM, Efebera YA, Hofmeister C, Jaglowski S, Devine S, Bhatt G, Wildes TM, Dyko A, Jones D, Naughton MJ, Byrd JC, Burd CE. Use of a comprehensive frailty assessment to predict morbidity in patients with multiple myeloma undergoing transplant. *J Geriatr Oncol*. 2019 May;10(3):479-485. PMID: PMC6320732
59. Wall SA, Zhao Q, Yearsley M, Blower L, Agyeman A, Ranganathan P, Yang S, Wu H, Bostic M, Jaglowski S, Brammer JE, William B, Choe H, Mims AS, Penza S, Efebera Y, Devine S, Cataland S, Davies SM, Vasu S. Complement-mediated thrombotic microangiopathy as a link between endothelial damage and steroid-refractory GVHD. *Blood Adv*. 2018 Oct 23;2(20):2619-2628. PMID: PMC6199668
60. Vaughn JL, Zhao Q, Epperla N, Puto M, Roddy J, Elder P, Blum W, Klisovic R, Jaglowski S, Penza S, William B, Andritsos L, Brammer JE, Hofmeister C, Efebera Y, Benson D, Devine S, Cataland S, Vasu S. Transplant-associated thrombotic microangiopathy: is the treatment more expensive than the disease? *Bone Marrow Transplant*. 2019 Jun;54(6):913-916.
61. Schuster SJ, Bishop MR, Tam CS, Waller EK, Borchmann P, McGuiRK JP, Jäger U, Jaglowski S, Andreadis C, Westin JR, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Pantano S, Pacaud LB, Awasthi R, Chu J, Anak Ö, Salles G, Maziarz RT, JULIET Investigators. Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma. *N Engl J Med*. 2019 Jan 03;380(1):45-56.
62. Singer S, Dean R, Zhao Q, Sharma N, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA. BEAM versus BUCYVP16 Conditioning before Autologous Hematopoietic Stem Cell Transplant in Patients with Hodgkin Lymphoma. *Biol Blood Marrow Transplant*. 2019 Jun;25(6):1107-1115.
63. Singer S, Sharma N, Dean R, Zhao Q, Abounader D, Elder P, Hofmeister CC, Benson DM, Rosko A, Penza S, Andritsos L, Vasu S, Jaglowski S, William BM, Bolwell B, Pohlman B, Kalaycio M, Jagadeesh D, Hill B, Sobecks R, Devine SM, Majhail NS, Efebera YA. BEAM or BUCYVP16-conditioning regimen for autologous stem-cell transplantation in non-Hodgkin's lymphomas. *Bone Marrow Transplant*. 2019 Oct;54(10):1553-1561.

64. Jaglowski SM, Blazar BR. How ibrutinib, a B-cell malignancy drug, became an FDA-approved second-line therapy for steroid-resistant chronic GVHD. *Blood Adv.* 2018 Aug 14;2(15):2012-2019. PMID: PMC6093735
65. Yucebay F, Matthews C, Puto M, Li J, William B, Jaglowski SM, Penza SL, Vasu S, Benson DM, Andritsos LA, Devine SM, Efebera YA, Roddy JVF. Tocilizumab as first-line therapy for steroid-refractory acute graft-versus-host-disease: analysis of a single-center experience. *Leuk Lymphoma.* 2019 Sep;60(9):2223-2229.
66. Vasu S, Jaglowski SM. Running the tank to empty: how far can the CAR go? *Blood.* 2019 Apr 11;133(15):1617-1618.
67. Vasu S, Jaglowski S. Have We Achieved a Goldilocks Grade of Graft-Versus-Host Disease? *Biol Blood Marrow Transplant.* 2019 Jun;25(6):e189-e190.
68. Waller EK, Miklos D, Cutler C, Arora M, Jagasia MH, Pusic I, Flowers MED, Logan AC, Nakamura R, Chang S, Clow F, Lal ID, Styles L, Jaglowski S. Ibrutinib for Chronic Graft-versus-Host Disease After Failure of Prior Therapy: 1-Year Update of a Phase 1b/2 Study. *Biol Blood Marrow Transplant.* 2019 Oct;25(10):2002-2007.
69. Pidala J, Jaglowski S, Im A, Chen G, Onstad L, Storer B, Kurukulasuriya C, Lee SJ. Carfilzomib for Treatment of Refractory Chronic Graft-versus-Host Disease: A Chronic GVHD Consortium Pilot Phase II Trial. *Biol Blood Marrow Transplant.* 2020 Feb;26(2):278-284.
70. Awasthi R, Pacaud L, Waldron E, Tam CS, Jäger U, Borchmann P, Jaglowski S, Foley SR, van Besien K, Wagner-Johnston ND, Kersten MJ, Schuster SJ, Salles G, Maziarz RT, Anak Ö, Del Corral C, Chu J, Gershgorin I, Pruteanu-Malinici I, Chakraborty A, Mueller KT, Waller EK. Tisagenlecleucel cellular kinetics, dose, and immunogenicity in relation to clinical factors in relapsed/refractory DLBCL. *Blood Adv.* 2020 Feb 11;4(3):560-572. PMID: PMC7013261
71. Maziarz RT, Waller EK, Jaeger U, Fleury I, McGuirk J, Holte H, Jaglowski S, Schuster SJ, Bishop MR, Westin JR, Mielke S, Teshima T, Bachanova V, Foley SR, Borchmann P, Salles GA, Zhang J, Tiwari R, Pacaud LB, Ma Q, Tam CS. Patient-reported long-term quality of life after tisagenlecleucel in relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv.* 2020 Feb 25;4(4):629-637. PMID: PMC7042998
72. Maakaron JE, Liscynsky C, Boghdadly ZE, Huang Y, Agyeman A, Brammer J, Penza S, Efebera Y, Benson D, Rosko A, William B, Jaglowski SM. Fluoroquinolone Prophylaxis in Autologous Stem Cell Transplantation: Worthy of a Second Look. *Biol Blood Marrow Transplant.* 2020 Aug;26(8):e198-e201.
73. Ardura M, Hartley D, Dandoy C, Lehmann L, Jaglowski S, Auletta JJ, Transplant-Associated Learning Network Team (TALNT). Addressing the Impact of the Coronavirus Disease 2019 (COVID-19) Pandemic on Hematopoietic Cell Transplantation: Learning Networks as a Means for Sharing Best Practices. *Biol Blood Marrow Transplant.* 2020 Jul;26(7):e147-e160. PMID: PMC7194714
74. Jacobson CA, Hunter BD, Redd R, Rodig SJ, Chen PH, Wright K, Lipschitz M, Ritz J, Kamihara Y, Armand P, Nikiforow S, Rogalski M, Maakaron J, Jaglowski S, Maus MV, Chen YB, Abramson JS, Kline J, Budde E, Herrera A, Mei M, Cohen JB, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. *J Clin Oncol.* 2020 Sep 20;38(27):3095-3106. PMID: PMC7499617
75. Bond DA, Huang Y, Fisher JL, Ruppert AS, Owen DH, Bertino EM, Rogers KA, Bhat SA, Grever MR, Jaglowski SM, Maddocks KJ, Byrd JC, Woyach JA. Second cancer incidence in CLL patients receiving BTK inhibitors. *Leukemia.* 2020 Dec;34(12):3197-3205. PMID: PMC7688551
76. Shea L, Watkins MP, Wan F, Cashen AF, Wagner-Johnston ND, Jacoby MA, Abboud CN, Dipersio JF, Hurd DD, Jaglowski SM, Bartlett NL, Fehniger TA. A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma. *Biol Blood Marrow Transplant.* 2020 Dec;26(12):2223-2228. PMID: PMC8212249
77. Jagers JL, Giri S, Klepin HD, Wildes TM, Olin RL, Artz A, Wall S, Jaglowski S, William B, Benson DM, Rosko AE. Characterizing inclusion and exclusion criteria in clinical trials for chimeric antigen receptor (CAR) T-cell therapy among adults with hematologic malignancies. *J Geriatr Oncol.* 2021 Mar;12(2):235-238.
78. DeFilipp Z, Burns LJ, Jaglowski SM, Leppin AL, Pavletic S, Waldman B, Weisdorf DJ, Wood WA, Khera N. A New Standard in Graft-versus-Host Disease Prophylaxis? An Introduction to Blood and Marrow Transplant Clinical Trials Network 1703. *Biol Blood Marrow Transplant.* 2020 Dec;26(12):e305-e308. PMID: PMC7735536
79. Kittai AS, Bond DA, William B, Saad A, Penza S, Efebera Y, Larkin K, Wall SA, Choe HK, Bhatnagar B,

- Vasu S, Brammer J, Shindiapina P, Long M, Mims A, O'Donnell L, Bhat SA, Rogers KA, Woyach JA, Byrd JC, Jaglowski SM. Clinical activity of axicabtagene ciloleucel in adult patients with Richter syndrome. *Blood Adv.* 2020 Oct 13;4(19):4648-4652. PMID: PMC7556158
80. Grana A, Gut N, Williams K, Maakaron J, Porter K, William BM, Vasu S, Penza S, Brammer JE, Saad A, Puto M, Jaglowski SM, Roddy J. Safety of Axicabtagene Ciloleucel for the Treatment of Relapsed or Refractory Large B-Cell Lymphoma. *Clin Lymphoma Myeloma Leuk.* 2021 Apr;21(4):238-245.
81. Pasquini MC, Hu ZH, Curran K, Laetsch T, Locke F, Rouce R, Pulsipher MA, Phillips CL, Keating A, Frigault MJ, Salzberg D, Jaglowski S, Sasine JP, Rosenthal J, Ghosh M, Landsburg D, Margossian S, Martin PL, Kamdar MK, Hematti P, Nikiforow S, Turtle C, Perales MA, Steinert P, Horowitz MM, Moskop A, Pacaud L, Yi L, Chawla R, Bleickardt E, Grupp S. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma. *Blood Adv.* 2020 Nov 10;4(21):5414-5424. PMID: PMC7656920
82. Kittai AS, Huang Y, Gordon M, Denlinger N, Mian A, Fitzgerald L, Bishop J, Nagle S, Stephens DM, Jaglowski S, Hill B, Danilov AV. Comorbidities Predict Inferior Survival in Patients Receiving Chimeric Antigen Receptor T Cell Therapy for Diffuse Large B Cell Lymphoma: A Multicenter Analysis. *Transplant Cell Ther.* 2021 Jan;27(1):46-52.
83. Sharma N, Zhao Q, Ni B, Elder P, Puto M, Benson DM, Rosko A, Chaudhry M, Devarakonda S, Bumma N, Khan A, Vasu S, Jaglowski S, William BM, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera Y. Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation. *Cancers (Basel).* 2021 Feb 04;13(4). PMID: PMC7913846
84. Merryman RW, Castagna L, Giordano L, Ho VT, Corradini P, Guidetti A, Casadei B, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Shah GL, Perales MA, De Colella JMS, Blaise D, Herrera AF, Shouse G, Spilleboudt C, Ansell SM, Nieto Y, Badar T, Hamadani M, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Nishihori T, Chavez J, Serritella AV, Kline J, Mohty M, Dulery R, Stamatoulas A, Houot R, Manson G, Moles-Moreau MP, Orvain C, Bouabdallah K, Modi D, Ramchandren R, Lekakis L, Beitinjaneh A, Frigault MJ, Chen YB, Lynch RC, Smith SD, Rao U, Byrne M, Romancik JT, Cohen JB, Nathan S, Phillips T, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Torri V, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani PL, Carlo-Stella C. Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma. *Leukemia.* 2021 Sep;35(9):2672-2683.
85. Miller CR, Huang Y, Ruppert AS, Labanowska J, Jaglowski SM, Maddocks KJ, Rogers KA, Bhat S, Kittai AS, Grever M, Lapalombella R, Abruzzo LV, Heerema NA, Byrd JC, Hertlein EK, Woyach JA. Significance of chromosome 2p gain in ibrutinib-treated chronic lymphocytic leukemia patients. *Leukemia.* 2021 Nov;35(11):3287-3290. PMID: PMC8490482
86. Sharma N, Faisal MS, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims AS, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Sigmund AM, Efebera YA. Outcomes of Bone Marrow Compared to Peripheral Blood for Haploidentical Transplantation. *J Clin Med.* 2021 Jun 27;10(13). PMID: PMC8268935
87. Nusbaum KB, Dulmage B, Choi JN, Jaglowski SM, Korman AM. Cutaneous manifestations of chimeric antigen receptor T-cell therapy: An introduction for dermatologists. *J Am Acad Dermatol.* 2022 Sep;87(3):597-604.
88. Brammer JE, Braunstein Z, Katapadi A, Porter K, Biersmith M, Guha A, Vasu S, Yildiz VO, Smith SA, Buck B, Haddad D, Gumina R, William BM, Penza S, Saad A, Denlinger N, Vallakati A, Baliga R, Benza R, Binkley P, Wei L, Mocarski M, Devine SM, Jaglowski S, Addison D. Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma. *J Immunother Cancer.* 2021 Aug;9(8). PMID: PMC8386216
89. Chin KK, Kim HT, Inyang EA, Ho V, Koreth J, Romee R, Gooptu M, Shapiro R, Antin J, Soiffer R, Jaglowski S, Pidala J, Cutler C. Ibrutinib in Steroid-Refractory Chronic Graft-versus-Host Disease, a Single-Center Experience. *Transplant Cell Ther.* 2021 Dec;27(12):990.e1-990.e7.
90. Herrera AF, Ahn KW, Litovich C, Chen Y, Assal A, Bashir Q, Bayer RL, Coleman M, DeFilipp Z, Farhadfar N, Greenwood M, Hahn T, Horwitz M, Jacobson C, Jaglowski S, Lachance S, Langston A, Mattar B, Maziarz RT, McGuirk J, Mian MAH, Nathan S, Phillips A, Rakszawski K, Sengeloev H, Shenoy S, Stuart R, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome. *Blood Adv.* 2021 Sep 28;5(18):3528-3539. PMID: PMC8945575
91. Schuster SJ, Tam CS, Borchmann P, Worel N, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR,

- Damon LE, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Janakiram M, Hsu JM, Izutsu K, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Martinez-Prieto M, Han X, Tiwari R, Salles G, Maziarz RT. Long-term clinical outcomes of tisagenlecleucel in patients with relapsed or refractory aggressive B-cell lymphomas (JULIET): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol.* 2021 Oct;22(10):1403-1415.
92. Ahmed S, Zhao Q, Hanel W, Qazilbash MH, Patel K, Narra R, Kansagra A, Iqbal M, Awan FT, Christian B, Jaglowski SM, Kharfan-Dabaja MA, Hamadani M, Epperla N. Post-relapse survival in Waldenstrom macroglobulinemia patients experiencing therapy failure following autologous transplantation. *Hematol Oncol.* 2022 Feb;40(1):48-56.
93. Schaefer A, Huang Y, Kittai A, Maakaron JE, Saygin C, Brammer J, Penza S, Saad A, Jaglowski SM, William BM. Cytopenias After CD19 Chimeric Antigen Receptor T-Cells (CAR-T) Therapy for Diffuse Large B-Cell Lymphomas or Transformed Follicular Lymphoma: A Single Institution Experience. *Cancer Manag Res.* 2021;13:8901-8906. PMID: PMC8643129
94. Vasu S, Bostic M, Zhao Q, Sharma N, Puto M, Knight S, Scott D, Guzman R, Kromer M, Tackett K, Lind K, Knill K, Watson E, Wall S, Saad A, Choe H, Larkin K, Brammer J, Jaglowski S, Penza S, Davies SM, Cataland S. Acute GVHD, BK virus hemorrhagic cystitis and age are risk factors for transplant-associated thrombotic microangiopathy in adults. *Blood Adv.* 2022 Feb 22;6(4):1342-1349. PMID: PMC8864665
95. Denlinger N, Bond D, Jaglowski S. CAR T-cell therapy for B-cell lymphoma. *Curr Probl Cancer.* 2022 Feb;46(1):100826. PMID: PMC9284423
96. Bajwa A, Huang Y, Li R, Denlinger N, Brammer J, Penza S, Saad A, Jaglowski S, Kittai AS. Prognostic value of early imaging following CAR-T cell therapy in diffuse large B-cell lymphoma. *Leuk Lymphoma.* 2022 Jun;63(6):1492-1495. PMID: PMC9284420
97. Bond DA, Huang Y, Christian BA, Jaglowski S, Benson D, Alinari L, Baiocchi RA, Cohen JB, Blum KA, Maddocks KJ. A phase I study of rituximab and buparlisib in patients with relapsed or refractory indolent non-Hodgkin lymphoma. *Leuk Lymphoma.* 2022 Jul;63(7):1750-1753.
98. Sigmund AM, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer J, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N. Impact of Race and Geographic Area of Residence on Outcomes After Allogeneic Stem Cell Transplant. *Front Oncol.* 2022;12:801879. PMID: PMC8913574
99. Sigmund AM, Denlinger N, Huang Y, Bond D, Voorhees T, Bajwa A, Elder P, Brammer JE, Saad A, Penza S, Vasu S, de Lima M, Jaglowski S, Kittai AS. Assessment of Salvage Regimens Post-Chimeric Antigen Receptor T Cell Therapy for Patients with Diffuse Large B Cell Lymphoma. *Transplant Cell Ther.* 2022 Jun;28(6):342.e1-342.e5. PMID: PMC9284421
100. Kapadia M, Lehmann L, Auletta J, Beatty L, Bhatt N, Blacken R, Demmel K, Dodd T, Desmond C, Fitch T, Flesch L, Hartley D, Huber J, Ingraham H, Jakubowski R, Klunk A, Krupski C, Kusnier K, Liberio N, Maakaron J, Mueller M, Myers KC, Pai A, Parker L, Patel S, Phelan R, Polishchuk V, Sigmund A, Sper C, Tarquini S, Juckett M, Jaglowski S, Dandoy C, Rotz S. Quality Improvement in Hematopoietic Stem Cell Transplant and Cellular Therapy: Using the Model for Improvement to impact Outcomes. *Transplant Cell Ther.* 2022 May;28(5):233-241.
101. Stephens DM, Huang Y, Ruppert AS, Walker JS, Canfield D, Cempre CB, Fu Q, Baker S, Hu B, Shah H, Vadeboncoeur R, Rogers KA, Bhat S, Jaglowski SM, Lockman H, Lapalombella R, Byrd JC, Woyach JA. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Safety in Advanced B-Cell Malignancies: A Phase I Study. *Clin Cancer Res.* 2022 Aug 02;28(15):3242-3247. PMID: PMC9364840
102. Jaeger U, Tam CS, Borchmann P, McGuirk JP, Johansen M, Waller EK, Jaglowski S, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles G, Schuster SJ, He F, Maziarz RT, Mayer S, Makita S, Kersten MJ, Ghosh M, Wagner-Johnston N, Kato K, Corradini P, Goto H, Colicino S, Agarwal A, Lobetti-Bodoni C, Bishop MR. Long-term safety for patients with tisagenlecleucel-treated relapsed/refractory diffuse large B-cell lymphoma. *Blood Adv.* 2022 Aug 23;6(16):4816-4820. PMID: PMC9631665
103. Elsayy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, Osman K, Davison K, Rudzki JD, Dahiya S, Dorritie K, Jaglowski S, Radford J, Morschhauser F, Cunningham D, Martin Garcia-Sancho A, Tzachanis D, Ulrickson ML, Karmali R, Kekre N, Thieblemont C, Enblad G, Dreger P, Malladi R, Joshi N, Wang WJ, Solem CT, Snider JT, Cheng P, To C, Kersten MJ. Patient-reported outcomes in ZUMA-7, a phase 3 study of axicabtagene ciloleucel in second-line large B-cell lymphoma. *Blood.* 2022 Nov 24;140(21):2248-2260. PMID: PMC10653042

104. Munshi PN, Chen Y, Ahn KW, Awan FT, Cashen A, Shouse G, Shadman M, Shaughnessy P, Zurko J, Locke FL, Goodman AM, Bisneto JCV, Sauter C, Kharfan-Dabaja MA, Meyers G, Jaglowski S, Herrera A, Hamadani M. Outcomes of Autologous Hematopoietic Cell Transplantation in Older Patients with Diffuse Large B-Cell Lymphoma. *Transplant Cell Ther.* 2022 Aug;28(8):487.e1-487.e7. PMID: PMC9375438
105. Sigmund AM, Huang Y, Ruppert AS, Maddocks K, Rogers KA, Jaglowski S, Bhat SA, Kittai AS, Grever MR, Byrd JC, Woyach JA. Depth of response and progression-free survival in chronic lymphocytic leukemia patients treated with ibrutinib. *Leukemia.* 2022 Aug;36(8):2129-2131.
106. Rotz SJ, Yi JC, Hamilton BK, Wei W, Preussler JM, Cerny J, Deol A, Jim H, Khera N, Hahn T, Hashmi SK, Holtan S, Jaglowski SM, Loren AW, McGuirk J, Reynolds J, Saber W, Savani BN, Stiff P, Uberti J, Wingard JR, Wood WA, Baker KS, Majhail NS, Syrjala KL. Health-Related Quality of Life in Young Adult Survivors of Hematopoietic Cell Transplantation. *Transplant Cell Ther.* 2022 Oct;28(10):701.e1-701.e7. PMID: PMC9547939
107. Koo J, Auletta JJ, Hartley DM, Huber J, Jaglowski S, Kapadia M, Kusnier K, Lehmann L, Maakaron J, Myers KC, Pai A, Parker L, Phelan R, Sper C, Rotz SJ, Dandoy CE. Secondary Impact of the Coronavirus Disease 19 Pandemic on Patients and the Cellular Therapy Healthcare Ecosystem. *Transplant Cell Ther.* 2022 Nov;28(11):737-746. PMID: PMC9313529
108. Hong S, Zhao J, Wang S, Wang H, Lee JH, Farhadfar N, McGuirk JP, Savani BN, Shahrukh HK, Stiff P, Khera N, Hahn T, Loren AW, Jaglowski SM, Wood WA, Saber W, Cerny J, Holtan SG, Reynolds JM, Deol A, Jim H, Uberti J, Whalen V, Yi JC, Preussler J, Baker KS, Shaw BE, Devine S, Syrjala K, Majhail NS, Wingard JR, Al-Mansour Z. Health-Related Quality of Life Outcomes in Older Hematopoietic Cell Transplantation Survivors. *Transplant Cell Ther.* 2023 Mar;29(3):202.e1-202.e8. PMID: PMC10165614
109. Jiang J, Sigmund AM, Zhao Q, Elder P, Benson DM, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer JE, Wall S, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N. Longitudinal Survival Outcomes in Allogeneic Stem Cell Transplantation: An Institutional Experience. *Cancers (Basel).* 2022 Nov 14;14(22). PMID: PMC9688916
110. Zurko J, Ramdial J, Shadman M, Ahmed S, Szabo A, Iovino L, Tomas AA, Sauter C, Perales MA, Shah NN, Acharya UH, Jacobson C, Soiffer RJ, Wang T, Komanduri KV, Jaglowski S, Kittai AS, Denlinger N, Iqbal M, Kharfan-Dabaja MA, Ayala E, Chavez J, Jain M, Locke FL, Samara Y, Budde LE, Mei MG, Pia AD, Feldman T, Ahmed N, Jacobs R, Ghosh N, Dholaria B, Oluwole OO, Hess B, Hassan A, Kenkre VP, Reagan P, Awan F, Nieto Y, Hamadani M, Herrera AF. Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma. *Haematologica.* 2023 Jan 01;108(1):98-109. PMID: PMC9827150
111. Faisal MS, Hanel W, Voorhees T, Li R, Huang Y, Khan A, Bond D, Sawalha Y, Reneau J, Alinari L, Baiocchi R, Christian B, Maddocks K, Efebera Y, Penza S, Saad A, Brammer J, DeLima M, Jaglowski S, Epperla N. Outcomes associated with allogeneic hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma in the era of novel agents. *Cancer Med.* 2023 Apr;12(7):8228-8237. PMID: PMC10134314
112. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Bouabdallah K, Khanal R, Topp MS, Houot R, Beitinjaneh A, Peng W, Fang X, Shen RR, Siddiqi R, Kloos I, Reagan PM. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study. *J Clin Oncol.* 2023 Jan 20;41(3):555-567. PMID: PMC9870225
113. Himed S, Chung C, Dulmage B, Jaglowski S, Bond D, Maddocks K, Kaffenberger BH. Development of recalcitrant cutaneous eruptions in patients with relapsed/refractory Hodgkin's lymphoma undergoing treatment with camidanlumab tesirine. *J Eur Acad Dermatol Venereol.* 2023 Jul;37(7):e890-e893.
114. Chakraborty R, Yi J, Rybicki L, Preussler J, Deol A, Loren A, Savani B, Jim HSL, Cerny J, Reynolds J, Whitten J, Wingard JR, McGuirk JP, Uberti J, Khera N, Stiff P, Jaglowski SM, Hashmi S, Holtan SG, Devine S, Hahn T, Whalen VL, Saber W, Wood W, Baker KS, Syrjala K, Majhail NS. Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. *Transplant Cell Ther.* 2023 Jun;29(6):388.e1-388.e6. PMID: PMC10718487
115. Gray AN, Avila C, Chung CG, Seminario-Vidal L, Mims A, Dulmage B, Larkin K, Choe H, Jaglowski S, Vasu S, Kaffenberger BH. Cutaneous graft-versus-host disease within chronic photodamaged skin: A case series demonstrating role for topical 5-fluorouracil. *JAAD Case Rep.* 2023 Jun;36:82-88. PMID: PMC10220457

116. Crees ZD, Rettig MP, Bashey A, Devine SM, Jaglowski S, Wan F, Zhou A, Harding M, Vainstein-Haras A, Sorani E, Gliko-Kabir I, Grossman BJ, Westervelt P, DiPersio JF, Uy GL. Hematopoietic stem cell mobilization for allogeneic stem cell transplantation by motixafortide, a novel CXCR4 inhibitor. *Blood Adv.* 2023 Sep 26;7(18):5210-5214. PMID: PMC10500469
117. Hanel W, Shindiapina P, Bond DA, Sawalha Y, Epperla N, Voorhees T, Welkie RL, Huang Y, Behbehani GK, Zhang X, McLaughlin E, Chan WK, Brammer JE, Jaglowski S, Reneau JC, Christian BA, William BM, Cohen JB, Baiocchi RA, Maddocks K, Blum KA, Alinari L. A Phase 2 Trial of Ibrutinib and Nivolumab in Patients with Relapsed or Refractory Classical Hodgkin's Lymphoma. *Cancers (Basel).* 2023 Feb 24;15(5). PMID: PMC10000669
118. Shouse G, Kaempf A, Gordon MJ, Artz A, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski S, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV. A validated composite comorbidity index predicts outcomes of CAR T-cell therapy in patients with diffuse large B-cell lymphoma. *Blood Adv.* 2023 Jul 25;7(14):3516-3529. PMID: PMC10362276
119. Ho VT, Klumpp TR, Liang WH, Prestegard M, Horwitz M, Hamilton BK, Page K, Jaglowski S, Huber J, Martinez C, Shenoy V, Chen A, Rizzo D. Cell Therapy Informatics: Updates on the Integration of HCT/IEC Functionalities into an Electronic Medical Record System in the US to Promote Efficiency, Patient Safety, Research, and Data Interoperability. *Transplant Cell Ther.* 2023 Sep;29(9):539-547.
120. Magenau J, Jaglowski S, Uberti J, Farag SS, Riwes MM, Pawarode A, Anand S, Ghosh M, Maciejewski J, Braun T, Devenport M, Lu S, Banerjee B, DaSilva C, Devine S, Zhang MJ, Burns LJ, Liu Y, Zheng P, Reddy P. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. *Blood.* 2024 Jan 04;143(1):21-31. PMID: PMC10934299
121. Kittai AS, Bond D, Huang Y, Bhat SA, Blyth E, Byrd JC, Chavez JC, Davids MS, Dela Cruz JP, Dowling MR, Duffy C, Ho C, Jacobson C, Jaglowski S, Jain N, Lin KH, Miller C, McCarthy C, Omer Z, Parry E, Rai M, Rogers KA, Saha A, Schachter L, Scott H, Senapati J, Shadman M, Siddiqi T, Stephens DM, Vanguru V, Wierda W, Woyach JA, Thompson PA. Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy for Richter Transformation: An International, Multicenter, Retrospective Study. *J Clin Oncol.* 2024 Jun 10;42(17):2071-2079.
122. Denlinger N, Song NJ, Zhang X, Jeon H, Peterson C, Wang Y, Reynolds K, Bolz RM, Miao J, Song C, Wu D, Chan WK, Bezerra E, Epperla N, Voorhees TJ, Brammer J, Kittai AS, Bond DA, Sawalha Y, Sigmund A, Reneau JC, Rubinstein MP, Hanel W, Christian B, Baiocchi RA, Maddocks K, Alinari L, Vasu S, de Lima M, Chung D, Jaglowski S, Li Z, Huang X, Yang Y. Postinfusion PD-1+ CD8+ CAR T cells identify patients responsive to CD19 CAR T-cell therapy in non-Hodgkin lymphoma. *Blood Adv.* 2024 Jun 25;8(12):3140-3153. PMID: PMC11222947
123. Voorhees TJ, Bezerra E, Denlinger N, Jaglowski S, de Lima M. SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program. *Clin Lymphoma Myeloma Leuk.* 2024 Oct;24(10):649-652.
124. Jiang J, Sigmund AM, Zhao Q, Elder P, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Wall S, Grieselhuber N, William B, Penza S, Benson DM, Efebera YA, Sharma N. Impact of chronic graft-versus-host disease on non-relapse mortality and survival. *Leuk Lymphoma.* 2024 Nov;65(11):1698-1705.
125. Dandoy CE, Adams J, Artz A, Bredeson C, Dahi PB, Dodd T, Jaglowski S, Lehmann L, LeMaistre CF, Mian A, Neal A, Page K, Rizzo JD, Rotz S, Sorrow M, Steinberg A, Viswabandya A, Howard DS, Committee on Quality Outcomes of the American Society of Transplant and Cellular Therapy. In Pursuit of Optimal Outcomes: A Framework for Quality Standards in Immune Effector Cell Therapy. *Transplant Cell Ther.* 2024 Oct;30(10):942-954.
126. Cusatis R, Litovich C, Feng Z, Allbee-Johnson M, Kapfhammer M, Mattila D, Akinola I, Phelan R, Broglie L, Auletta JJ, Steinert P, Bolon YT, Akhtar O, Bloomquist J, Chen M, Devine SM, Bupp C, Hamadani M, Hengen M, Jaglowski S, Kaur M, Kuxhausen M, Lee SJ, Moskop A, Page KM, Pasquini MC, Rizzo D, Saber W, Spellman SR, Stefanski HE, Tuschl E, Yusuf R, Zhan K, Flynn KE, Shaw BE. Current Trends and Outcomes in Cellular Therapy Activity in the United States, Including Prospective Patient-Reported Outcomes Data Collection in the Center for International Blood and Marrow Transplant Research Registry. *Transplant Cell Ther.* 2024 Sep;30(9):917.e1-917.e12. PMID: PMC11587342
127. Pidala JA, Kim J, Kalos D, Cutler CS, DeFilipp Z, Flowers ME, Hamilton BK, Chin KK, Rotta M, El Jurdi N, Hamadani M, Ahmed G, Kitko CL, Ponce DM, Sung AD, Tang H, Farhadfar N, Nemecek ER, Pusic I, Qayed M, Rangarajan HG, Hogan WJ, Etra AM, Jaglowski SM. Ibrutinib for therapy of

steroid-refractory chronic graft vs. host disease: A multicenter real-world analysis. *Blood Adv.* 2024 Oct 25.

Abstracts

1. Jaglowski SM, Byrd JC, Jones JA. In-Hospital Mortality and Trends Associated with Splenectomy in Patients with Immune-Mediated Thrombocytopenia (ITP). *Blood.* 2009 Nov 20;114(22):1398. Poster presentation at 51st American Society of Hematology Annual Meeting, December 2009; New Orleans, Louisiana.
2. Jaglowski SM, Lin TL, Elder P, Scholl D, Byrd JC, Devine SM, Andritsos LA. Barriers to Reduced-Intensity Conditioning (RIC) Transplant in Patients with Chronic Lymphocytic Leukemia. *Blood.* 2009 Nov 20;114(22):1374. Poster presentation at 51st American Society of Hematology Annual Meeting, December 2009; New Orleans, Louisiana.
3. Jaglowski SM, Heerema N, Elder P, Scholl D, Hamadani M, Byrd JC, Devine SM, Andritsos LA. Complex Karyotype Predicts Poor Response to Salvage Therapy and Ineligibility for Reduced Intensity Conditioning Transplantation in CLL. *Biology of Blood and Marrow Transplantation.* 2010 Feb;16(2):S282–S283. Poster presentation at American Society for Blood and Marrow Transplantation Annual Meeting, February 2010; Orlando, Florida.
4. Jaglowski SM, Flynn JM, Jones JA, Lin TS, Fischer B, Scholl D, Elder P, Devine SM, Grever MR, Byrd JC, and Andritsos LA. Flavopiridol is an Effective Therapy to Bridge Patients with Chronic Lymphocytic Leukemia (CLL) to Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant. *Blood.* 2011 Nov 18;118(21):2283. Poster presentation at: 53rd ASH Annual Meeting, December 2011; San Diego, California.
5. Jaglowski SM, Heerema NA, Elder P, Byrd JC, Devine SM, and Andritsos LA. Increasing Genetic Complexity Predicts for Inferior Outcomes Following Reduced-Intensity Conditioning Allogeneic Transplant for Chronic Lymphocytic Leukemia. *Blood.* 2011 Nov 18;118(21):3090. Poster presentation at: 53rd ASH Annual Meeting, December 2011; San Diego, California.
6. Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Blum KA, Grever MR, Geyer S, Woyach JA, Johnson AJ, Heerema NA, Molnar E, Stefanos M, Devlin S, Navarro T, James D, Lowe A, Hedrick E, Byrd JC. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases. *J Clin Oncol.* 2012 May 20;30(15_suppl):6508. Oral presentation at: ASCO Annual Meeting, June 2012; Chicago, Illinois.
7. Jaglowski SM, Vasu S, Geyer S, Bingman A, Elder P, Yu J, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Andritsos LA, Lozanski G. Immune Reconstitution at Days 30 and 100 Following Allogeneic Stem Cell Transplant and Association with Subsequent Development of Chronic Graft-Versus-Host Disease. *Blood.* 2012 Nov 16;120(21):1949. Poster presentation at: 54th Annual ASH Annual Meeting, December 2012; Atlanta, Georgia.
8. Jaglowski SM, Hofmeister CC, Elder P, Penza S, Efebera YA, Benson DM, Devine SM, Andritsos LA. The hematopoietic stem cell transplant comorbidity index (HCT-CI) can predict for readmission following autologous stem cell transplant for lymphoma and multiple myeloma. *Blood.* 2012 Nov 16;120(21):4286. Poster presentation at: 54th Annual ASH Annual Meeting, December 2012; Atlanta, Georgia.
9. Hamadani M, Craig M, Remick S, Gibson L, Petros W, Abraham J, Cumpston A, Bunner P, Basu S, Tse W, Hennelly C, Vasu S, Klisovic RB, Blum W, Jaglowski SM, Benson DM, Andritsos LA, Penza S, Hofmeister CC, Geyer S, Devine SM, Efebera YA. Immunomodulation of both donors and recipients with atorvastatin as a strategy for the prevention of acute graft-versus-host disease (aGVHD): results of two parallel prospective trials in recipients of matched sibling allogeneic hematopoietic cell transplantation (alloHCT). *Blood.* 2012 Nov 16;120(21):1942. Poster presentation at: 54th Annual ASH Annual Meeting, December 2012; Atlanta, Georgia.
10. Dubovsky JA, Beckwith KA, Woyach JA, Jaglowski SM, Hessler J, Chang BY, Larkin K, Stefanovski MR, Frizzera FW, Smith LL, Smucker KA, Flynn JM, Jones JA, Andritsos LA, Maddocks K, Lehman A, Furman RR, Sharman J, Mishra A, Caligiuri MA, Buggy JJ, Muthusamy N, Johnson AJ, Byrd JC. Ibrutinib is an irreversible molecular inhibitor of interleukin-2 inducible kinase: expanding therapeutic potential and modulating a TH1 selective pressure in CD4 T-cells. *Blood.* 2012 Nov 16;120(21):775. Poster presentation at: 54th Annual ASH Annual Meeting, December 2012; Atlanta, Georgia.
11. Yu J, He S, Wu L, Mao H, Vasu S, Jaglowski SM, Peng Y, Alvarez-Breckenridge C, Yuan S, Wei M, Zhang J, Hughes TL, Ghoshal K, Devine SM, Caligiuri MA. MicroRNAs promote activation and maturation

- of natural killer cells through toll-like receptor signaling. *Blood*. 2012 Nov 16;120(21):2160. Poster presentation at: 54th Annual ASH Annual Meeting, December 2012; Atlanta, Georgia.
12. Blum KA, Christian B, Flynn JM, Jaglowski SM, Jones JA, Maddocks K, Byrd JC. A phase I trial of the Bruton's Tyrosine Kinase (BTK) inhibitor ibrutinib (PCI-32765) in combination with rituximab (R) and bendamustine in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL). *Blood*. 2012 Nov 16;120(21):1643. Poster presentation at: 54th Annual ASH Annual Meeting, December 2012; Atlanta, Georgia.
 13. Vasu S, Jaglowski SM, Geyer S, Bingman A, Elder P, Yu J, Andritsos LA, Blum W, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Devine SM, Lozanski G. Differential distribution of activated innate and adaptive immune subsets in G-CSF mobilized hematopoietic stem cell allografts may influence incidence of acute (aGVHD) and chronic graft-versus-host disease (cGVHD). *Blood*. 2012 Nov 16;120(21):4192. Poster presentation at: 54th Annual ASH Annual Meeting, December 2012; Atlanta, Georgia.
 14. Efebera Y, Geyer S, Bingman A, Kitzler R, Elder P, Hennelly C, Andritsos LA, Jaglowski S, Blum W, Klisovic R, Penza S, Vasu S, Hofmeister CC, Benson DM, Devine SM, Lozanski G. Impact of atorvastatin on cellular immunome of patients undergoing allogeneic hematopoietic stem cell transplantation (AH SCT). *Biol Blood Marrow Transplant*. 2013 Feb;19(2):178. Poster presentation at: ASBMT Annual Meeting, February 2013; Salt Lake City, Utah.
 15. Pandit A, Wei L, Elder P, Falk W, Sell M, Hofmeister C, Benson D, Penza S, Andritsos L, Vasu S, Blum W, Devine S, Jaglowski S, Efebera Y. Autologous hematopoietic stem cell transplant (aHSCT) is a safe and reasonable treatment in patients with primary systemic amyloidosis (AL amyloidosis). *Biol Blood Marrow Transplant*. 2013 Feb;19(2):145. Poster presentation at: ASBMT Annual Meeting, February 2013; Salt Lake City, Utah.
 16. Salem G, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R, Vasu S, Blum W, Devine SM, Jaglowski S, Efebera Y. Lower dose of antithymocyte globulin (ATG) decreases infection rate without increasing graft-vs-host disease (GVHD) and relapse in patients undergoing reduced-intensity (RIC) allogeneic hematopoietic stem cell transplant (HSCT). *Biol Blood Marrow Transplant*. 2013 Feb;19(2):S304–S305. Poster presentation at: ASBMT Annual Meeting, February 2013; Salt Lake City, Utah.
 17. El-Jawahri A, Pidala J, Chai X, Wood WA, Khera N, Arora M, Jaglowski SM, Lee SJ, Chen Y. Do older patients with moderate-severe chronic graft-versus-host disease differ from younger patients? *Blood*. 2013 Nov 15;122(21):725. Poster presentation at: 55th Annual ASH Annual Meeting, December 2013; New Orleans, Louisiana.
 18. Stephens D, Ruppert AS, Wierda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam CS, O'Brien S, Keating MJ, Muthusamy R, Abruzzo LV, Heerema NA, Byrd JC. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. *Blood*. 2013 Nov 15;122(21):4128. Poster presentation at: 55th Annual ASH Annual Meeting, December 2013; New Orleans, Louisiana.
 19. Stephens D, Ruppert AS, Wierda WG, Jones JA, Woyach JA, Maddocks K, Jaglowski SM, Andritsos LA, Flynn JM, Grever MR, Lozanski G, Tam CS, O'Brien S, Keating MJ, Muthusamy R, Abruzzo LV, Heerema NA, Byrd JC. Externally validated predictive clinical model for untreated del(17p13.1) chronic lymphocytic leukemia patients. *Blood*. 2013 Nov 15;122(21):4128. Poster presentation at: 55th Annual ASH Annual Meeting, December 2013; New Orleans, Louisiana.
 20. Haverkos BM, Geyer S, McBride A, Penza S, Devine SM, Andritsos LA, Jaglowski S. Mobilization for Autologous Stem Cell Transplantation in Hodgkin's Lymphoma and Non-Hodgkin's Lymphoma: A Single Institution Experience. *Biol Blood Marrow Transplant*. 2014 Feb;20(2):S111-112. Poster presentation at: ASBMT Annual Meeting, February 2014; Dallas, Texas.
 21. El-Jawahri A, Pidala J, Chai X, Wood WA, Khera N, Arora M, Jaglowski S, Lee SJ, Chen Y. The Impact of Age on Quality of Life, Functional Status, and Overall Survival in Patients with Moderate-Severe Chronic Graft-versus-Host Disease. *Biol Blood Marrow Transplant*. 2014 Feb;20(2):S65. Poster presentation at: ASBMT Annual Meeting, February 2014; Dallas, Texas.
 22. McBride A, Geyer S, Jaglowski S, Devine SM, Andritsos LA. Plerixafor Mobilization in MM Patients and Impact on CD34 Cell Collection and Transplant Outcomes. *Biol Blood Marrow Transplant*. 2014 Feb;20(2):S293. Poster presentation at: ASBMT Annual Meeting, February 2014; Dallas, Texas.
 23. Jaglowski SM, Jones JA, Flynn JM, Andritsos LA, Maddocks KJ, Woyach JA, Blum KA, Grever MR, Geyer SM, Heerema NA, Lozanski G, Stefanos M, Hall N, Nagar V, Munneke B, West J, Neuenburg J, James DF, Johnson AJ, Byrd JC. A Phase 1b/2 Study Evaluating Activity and Tolerability of the BTK

- Inhibitor Ibrutinib in Combination with Ofatumumab in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) and Related Diseases. *J Clin Oncol*. 2014 May 20;32(15_suppl):7009. Poster presentation at: ASCO Annual Meeting, May 2014; Chicago, Illinois.
24. Woyach JA, Ruppert AS, Lozanski G, Lozanski A, Heerema NA, Zhao W, Abruzzo L, Gordon A, Jones JA, Flynn JM, Jaglowski SM, Andritsos LA, Awan F, Blum KA, Grever MR, Johnson AJ, Byrd JC, Maddocks KJ. Association of Disease Progression on Ibrutinib Therapy with the Acquisition of Resistance Mutations: A Single-Center Experience of 267 Patients. *J Clin Oncol*. 2014 May 20;32(15_suppl):7010. Poster presentation at: ASCO Annual Meeting, May 2014; Chicago, Illinois.
 25. Efebera YA, Geyer S, Bingman A, Kitzler R, Elder P, Andritsos LA, Jaglowski SM, Vasu S, Blum W, Klisovis RB, Penza S, Coombes K, Hofmeister CC, Benson D, Devine SM, Lozanski G. Impact of Atorvastatin on Cellular Immunome of Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*. 2014 Dec 6;124(21):1166. Poster presentation at: 56th ASH Annual Meeting, December 2014; San Francisco, California.
 26. Coutre S, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJS, Mato AR, Miklos DB, Keating M, Zhou C, Fardis M, Styles L, Jaglowski S. Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant. *Blood*. 2014 Dec 6;124(21):4697. Poster presentation at: 56th ASH Annual Meeting, December 2014; San Francisco, California.
 27. Haverkos BM, Cortright K, Andritsos LA, Blum W, Klisovic RB, Vasu S, Goldenberg DM, Wegener WA, Devine SM, Jaglowski SM. A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies. *Blood*. 2014 Dec 6;124(21):1168. Poster presentation at: 56th ASH Annual Meeting, December 2014; San Francisco, California.
 28. Vasu S, Bingman A, Geyer S, Elder P, Kitzler R, Bradbury H, O'Donnell L, Blum W, Jaglowski SM, Andritsos LA, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Benson DM, Muthusamy N, Lozanski G, Devine SM. Allograft T-Cell, T-Regs, NK-Cell and B-Cell Content Influence Distinct Clinical Outcomes Following G-CSF Mobilized Hematopoietic Stem Cell Transplantation. *Blood*. 2014 Dec 6;124(21):2494. Poster presentation at: 56th ASH Annual Meeting, December 2014; San Francisco, California.
 29. Guinn D, Ruppert AS, Maddocks KJ, Jaglowski SM, Gordon AL, Lin TS, Larson RA, Marcucci G, Hertlein EK, Woyach JA, Johnson AJ, Byrd JC. Mir-155 Expression is Associated with Chemoimmunotherapy Outcome and is Modulated by Bruton's Tyrosine Kinase Inhibition with Ibrutinib. *Blood*. 2014 Dec 6;124(21):3297.
 30. Maddocks KJ, Cohen JB, Christian B, Flynn JM, Jaglowski SM, Blum KA. A Phase II Study of MLN8237 (Alectinib) Alone and in Combination with Rituximab in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas. *Blood*. 2014 Dec 6;124(21):3082. Poster presentation at: 56th ASH Annual Meeting, December 2014; San Francisco, California.
 31. Christian B, Wei L, Sexton J, Jaglowski SM, Devine SM, Fehniger TA, Wagner-Johnston N, Bartlett NL, Blum KA. A Phase I/II Trial of the Histone Deacetylase (HDAC) Inhibitor Panobinostat, in Combination with Lenalidomide in Patients with Relapsed/Refractory Hodgkin's Lymphoma. *Blood*. 2014 Dec 6;124(21):3099. Poster presentation at: 56th ASH Annual Meeting, December 2014; San Francisco, California.
 32. Rogers KA, Woyach JA, Andritsos LA, Awan F, Blum KA, Flynn JM, Jaglowski S, Lozanski G, Maddocks KJ, Byrd JC, Jones JA. Incidence of Autoimmune Cytopenias in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma Patients Treated with Ibrutinib. *Blood*. 2014 Dec 6;124(21):1997. Poster presentation at: 56th ASH Annual Meeting, December 2014; San Francisco, California.
 33. Efebera YA, Geyer S, Bingman A, Elder P, Kitzler R, Coombes K, Hennesly C, Cortright K, Andritsos LA, Jaglowski SM, Vasu S, Blum W, Klisovic RB, Penza S, Hofmeister CC, Benson DM, Lozanski G, Devine SM. Phase II Trial Evaluating the Safety and Efficacy of Atorvastatin for the Prophylaxis of Acute Graft versus Host Disease in Patients with Hematological Malignancies Undergoing HLA-Matched Related Donor Allogeneic Hematopoietic Stem Cell Transplantation. *Blood*. (ASH Annual Meeting Abstracts) 2014; 124:3929
 34. Miklos DB, Coutre S, O'Brien S, Byrd JC, Hillmen P, Brown JR, Dyer M, Mato AR, Keating M, Zhou C, Fardis M, Styles L, Jaglowski S. Safety and Efficacy of Ibrutinib in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Who Have Undergone Prior Allogeneic Stem Cell Transplant. *Biol Blood Marrow Transplant*. 2015 Feb;21(2):S82-S83. ASBMT Annual Meeting, February 2015; San Diego, California.

35. Arai S, Pidala J, Pusic I, Chai X, Jaglowski S, Palmer J, Chen GL, Khera N, Mayer S, Jagasia MH, Wood WA, Martin PJ, Inamoto Y, Miklos DB, Lee SJ, Flowers MED. A Randomized Phase II Study of Imatinib and Rituximab for Cutaneous Sclerosis after Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2015 Feb;21(2):S324. ASBMT Annual Meeting, February 2015; San Diego, California.
36. Haverkos B, Cortright K, Andritsos LA, Blum W, Klisovic R, Vasu S, Goldenberg DM, Wegener W, Devine SM, Jaglowski S. A Phase I Study of Milatuzumab for Prevention of Acute Graft Versus Host Disease Following Reduced-Intensity Conditioning Allogeneic Stem Cell Transplant in Patients with Hematologic Malignancies. *Biol Blood Marrow Transplant*. 2015 Feb;21(2):S331–S332. ASBMT Annual Meeting, February 2015; San Diego, California.
37. Miklos DB, Arora M, Cutler CS, Nakamura R, Juretic M, Li Y, Styles LA, James DF, Jaglowski SM. A multicenter open-label phase 1b/2 study of ibrutinib in steroid dependent or refractory chronic graft versus host disease (cGVHD). *J Clin Oncol*. 2015 May 20;33(15_suppl):7024. Poster presentation at: ASCO Annual Meeting, May 2015; Chicago, Illinois.
38. Rosko AE, Hofmeister CC, Efebera YA, Benson DM, Sborov DW, Jaglowski S, Devine S, Wildes TM, Gillahan J, Jones D, Huang Y, Burd CE. Geriatric Assessment Metrics Are Associated with Hospital Length of Stay in Pre-Bone Marrow Transplant Myeloma Patients. *Blood*. 2015 Dec 3;126(23):3200. Poster presentation at: 57th ASH Annual Meeting, December 2015; Orlando, Florida.
39. O'Brien S, Jaglowski S, Byrd JC, Bannerji R, Blum K, Fox CP, Furman RR, Hillmen P, Kipps TJ, Montillo M, Sharman J, Suzuki S, James D, Chu AD, Coutre S. Analysis of Prognostic Factors Predictive of Complete Response (CR) to Ibrutinib in Patients with CLL/SLL. *Blood*. 2015 Dec 3;126(23):4153. Poster presentation at: 57th ASH Annual Meeting, December 2015; Orlando, Florida.
40. Issa H, Sharma N, Zhao Q, Ruppert AS, Elder P, Benson DM, Penza S, Vasu S, William B, Jaglowski S, Devine SM, Efebera YA. Comparison of Two Doses of Antithymocyte Globulin in Reduced-Intensity Conditioning Allogeneic Hematopoietic Stem Cell Transplantation. *Biol Blood Marrow Transplant*. 2019 Oct;25(10):1993-2001.
41. Issa H, Ruppert AS, Elder P, Hofmeister CC, Benson DM, Penza S, Andritsos LA, Klisovic R, Vasu S, Blum W, Jaglowski S, Devine SM, Efebera YA. Antithymocyte Globulin (ATG) 4.5 vs 6.0 mg/kg in Reduced Intensity Conditioning (RIC) Allogeneic Hematopoietic Stem Cell Transplant (alloHSCT). *Biol Blood Marrow Transplant*. 2016 Mar;22(3):S316–S317. Poster presentation at: ASBMT Annual Meeting, February 2016; Honolulu, Hawaii.
42. Jaglowski S, Waller EK, Kindwall-Keller TL, McCarty JM, Dugan M, Yellin M, Davis T, Devine SM. Preliminary Safety and Efficacy Data Using CDX-301 (Flt3 ligand) as a Sole Agent to Mobilize Hematopoietic Cells Prior to HLA-Matched Sibling Donor Transplantation. *Biol Blood Marrow Transplant*. 2016 Mar;22(3):S324–S325. Poster presentation at: ASBMT Annual Meeting, February 2016; Honolulu, Hawaii.
43. Rotta M, Wei L, Kitzler R, Bradbury H, Bingman A, Vasu S, Jaglowski S, Blum W, Klisovic R, Penza S, Andritsos LA, Efebera YA, Lozanski G, Devine SM. Significant Impact of Mobilization Strategy on the Cellular Composition of Donor Allografts. *Biol Blood Marrow Transplant*. 2016 Mar;22(3):S351–S352. Poster presentation at: ASBMT Annual Meeting, February 2016; Honolulu, Hawaii.
44. Miklos D, Cutler C, Arora M, Waller E, Jagasia M, Nakamura R, Blazar B, Juretic M, Li Y, Dubovsky J, James D, Styles L, Jaglowski S. Multicenter Open-Label Phase 1b/2 Study of Ibrutinib in Steroid-Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD). *Bone Marrow Transplant*. 2016 Mar 1 [cited 2023 Jan 23];51(S1):S176-S177. Poster presentation at: 42nd Annual Meeting of the European Society for Blood and Marrow Transplantation, April 2016; Valencia, Spain.
45. Woyach JA, Guinn D, Ruppert AS, Blachly JS, Lozanski A, Heerema NA, Zhao W, Coleman J, Jones D, Abruzzo LV, Gordon A, Mantel R, Smith LL, McWhorter S, Davis M, Doong T, Ny F, Lucas MS, Chase W, Jones J, Flynn JM, Maddocks KJ, Jaglowski S, Andritsos LA, Awan FT, Blum K, Grever MR, Lozanski G, Byrd JC, Johnson AJ. The Development and Expansion of Resistant Subclones Precedes Relapse during Ibrutinib Therapy in Patients with CLL. *Blood*. 2016 Dec 2;128(22):55. Poster presentation at: 58th ASH Annual Meeting, December 2016; San Diego, California.
46. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung H, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Jain RK, Rao AV, Reagan PM. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma. *N Engl J Med*. 2020 Apr 02;382(14):1331-1342. PMID: PMC7731441

47. Richardson DR, Huang Y, Elder P, Newlin J, Kirkendall C, Devine SM, Andritsos LA, Benson DM, Blum W, Efebera YA, Hofmeister CC, Jaglowski S, Klisovic RV, McGinty HL, Penza S, Vasu S, William BM, Rosko AE. Psychosocial Risk is Associated with High Readmission Rates and Increased Length of Stay for Patients Following Hematopoietic Stem Cell Transplantation. *Blood*. 2016 Dec 2;128(22):3198. Poster presentation at: 58th ASH Annual Meeting, December 2016; San Diego, California.
48. Wiczer TE, Levine LB, Brumbaugh J, Coggins J, Zhao Q, Ruppert AS, McCoy A, Maddocks KJ, Christian BA, Rogers KA, Andritsos L, Jaglowski S, Devine SM, Porcu P, Woyach JA, Jones J, Grever MR, Byrd JC, Awan FT. Management and Outcomes of Atrial Fibrillation in Patients Receiving Ibrutinib for Hematologic Malignancies at a Single Center. *Blood*. 2016 Dec 2;128(22):2040. Poster Presentation at: 58th ASH Annual Meeting, December 2016; San Diego, California.
49. Miller CR, Ruppert AS, Heerema NA, Maddocks KJ, Labanowska J, Breidenback H, Lozanski G, Zhao W, Gordon A, Jones J, Flynn JM, Jaglowski S, Andritsos LA, Awan FT, Blum KA, Grever MR, Johnson AJ, Abruzzo LV, Kertlein EK, Woyach JA, Byrd JC. Near-Tetraploidy is Strongly Associated with Development of Richter's Transformation in Chronic Lymphocytic Leukemia Patients Receiving Ibrutinib. *Blood*. 2016 Dec 2;128(22):3198. Poster presentation at: 58th ASH Annual Meeting, December 2016; San Diego, California.
50. Auletta JJ, Ardura JI, Vasu S, Huang Y, Zhao Q, Ruppert AS, Shoben A, Elder P, Bingman A, Kitzler R, Lozanski G, Abu-Arja R, Rangarajan HG, Bajwa R, Horwitz EM, O'Donnell L, Jaglowski S, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Rosko AE, Benson DM, Andritsos LA, Blum W, Devine SM. Cytomegalovirus Reactivation Does Not Increase Subsequent Risk for Acute Graft-versus-Host Disease, Malignant Disease Relapse, or Infection Following Allogeneic Hematopoietic Cell Transplantation. *Blood*. 2016 Dec 2;128(22):3409. Poster presentation at: 58th ASH Annual Meeting, December 2016; San Diego, California.
51. Auletta JJ, Ardura JI, Vasu S, Huang Y, Zhao Q, Ruppert AS, Shoben A, Elder P, Bingman A, Kitzler R, Lozanski G, Abu-Arja R, Rangarajan HG, Bajwa R, Horwitz EM, O'Donnell L, Jaglowski S, Klisovic RB, Penza S, Efebera YA, Hofmeister CC, Rosko AE, Benson DM, Andritsos LA, Blum W, Devine SM. Early Infection Attenuates Hematologic Malignant Disease Relapse Following Initial Allogeneic Hematopoietic Cell Transplantation. *Blood*. 2016 Dec 2;128(22):3410. Poster presentation at: 58th ASH Annual Meeting, December 2016; San Diego, California.
52. Richardson DR, Zhao Q, Kitzler R, Elder P, Lozanski G, Andritsos LA, Benson DM, Blum W, Efebera YA, Jaglowski S, Klisovic RB, Penza S, Vasu S, Devine SM. Doses of Total Nucleated Cells and Activated T-Cells Transplanted Influence Survival and Graft Versus Host Disease Among AML and MDS Recipients of Reduced-Intensity Mobilized Peripheral Blood Allografts. *Blood*. 2016 Dec 2;128(22):4598. Poster presentation at: 58th ASH Annual Meeting, December 2016; San Diego, California.
53. Miklos D, Cutler CS, Auror M, Waller EK, Jagasia M, Pusic I, Flowers ME, Logan AC, Nakamura R, Blazar BR, Li Y, Lai I, Dubovsky J, James DF, Styles L, Jaglowski S. Multicenter Open-Label Phase 2 Study of Ibrutinib in Chronic Graft Versus Host Disease (cGVHD) after Failure of Corticosteroids. *Blood*. 2016 Dec 2;128(22):LBA-3-LBA-3. Poster presentation at: 58th ASH Annual Meeting, December 2016; San Diego, California.
54. Epperla N, Ahn KW, DiGilio A, Jagasia M, Armand P, Ahmed S, Devine SM, Jaglowski S, Kharfan-Dabaja MA, Kennedy V, Rezvani A, Smith SM, Sureda A, Fenske TS, Hamadani M. Rituximab (R) Versus Non-Rituximab (NR) Containing Reduced Intensity Conditioning (RIC) Regimens for Allogeneic Hematopoietic Cell Transplantation (alloHCT) in B-Cell Non-Hodgkin Lymphomas (B-NHL): A CIBMTR Analysis. *Biol Blood Marrow Transplant*. 2017 Mar; 23(3):S47–S48. Poster presentation at: ASBMT Annual Meeting, February 2017; Orlando, Florida.
55. Chen GL, Onstad L, Martin PJ, Pidala JA, Jagasia M, Khera N, Palmer J, Arai S, Jaglowski S, Mayer S, Pusic I, Wood WA, Flowers ME, Lee SJ, Inamoto Y. Analysis of Pulmonary Function Change Associated with Sclerotic Chronic Graft Versus Host Disease (ScGVHD). *Biol Blood Marrow Transplant*. 2017 Mar; 23(3):S361–S362. Poster presentation at: ASBMT Annual Meeting, February 2017; Orlando, Florida.
56. Schuster SJ, Bishop MR, Tam C, Waller EK, Borchmann P, McGuirk J, Jager U, Jaglowski S, Andreadis C, Westin J, Fleury I, Bachanova V, Foley SR, Ho PJ, Mielke S, Magenau JM, Holte H, Anak O, Pacaud L, Awasthi R, Tai F, Salles G, Maziarsz RT. Global Pivotal Phase 2 Trial of the CD19-Targeted Therapy CTL019 in Adult Patients with Relapsed or Refractory (R/R) Diffuse Large B Cell Lymphoma (DLBCL) – An Interim Analysis. *Haematologica*. Oral presentation at: 22nd European

- Hematology Association Congress Late Breaking Abstracts, June 2017; Madrid, Spain.
57. Schuster SJ, Bishop MR, Tam C, Borchmann P, Jaeger U, Waller EK, Holte H, McGuirk JP, Jaglowski S, Tobinai K, Andreadid C, Fleury I, Mielke S, Teshima T, Westin JR, Bachanova V, Foley SR, Ho PJ, Magenau JM, Wagner-Johnston ND, Kato K, Kersten MJ, Van Besien K, Chu J, Jary A, Anak O, Salles G, Maziarz RT. Sustained Disease Control for Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma: an Updated Analysis of Juliet, a Global Pivotal Phase 2 Trial of Tisagenlecleucel. *Blood*. 2018 Nov 29;132(Supplement 1):1884. Poster presentation at: 60th ASH Annual Meeting, December 2018; San Diego, California.
 58. Rettig MP, Uy GL, Bashey A, Devine S, Jaglowski S, Vainstein A, Sorani E, Chen H, Bohana-Kashtan O, Shaw S, Westervelt P, DePersio JF. Phase II Study Evaluating the Safety and Efficacy of BL-8040 for the Mobilization of Donor Hematopoietic Stem and Progenitor Cells for Allogeneic Hematopoietic Cell Transplantation and Phenotypic Characterization of the Leukapheresis Product. *Blood*. 2018 Nov 29;132(Supplement 1):118. Poster presentation at: 60th ASH Annual Meeting, December 2018; San Diego, California.
 59. Jacobson CA, Hunter B, Armand P, Kamihara Y, Ritz J, Rodig SJ, Wright K, Lipschitz M, Redd RA, Maus MV, Chen Y, Abramson JS, Kline J, Cohen JB, Maakaron J, Jaglowski S, Smith SD, Maloney DG, Gopal AK, Frigault MJ, Acharya UH. Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. *Blood*. 2018 Nov 29;132(Supplement 1):92. Poster presentation at: 60th ASH Annual Meeting, December 2018; San Diego, California.
 60. Rasor B, Dickerson T, Zhao Q, Elder P, Brammer JE, Larkin K, Jaglowski S, Mims A, Penza S, Vasu S, Wall SA, William B, Saad A, Roddy JVF, Choe H, Puto M. Comparison of fixed dose reduced-intensity conditioning with fludarabine and busulfan to PK-guided busulfan AUC (FluBu4K) in hematopoietic stem cell transplant for AML/MDS. *Leuk Lymphoma*. 2021 Apr;62(4):944-951. PMID: PMC8012251
 61. Flinn IW, Cohen JB, Akard LP, Jaglowski S, Vasconcelles M, Ranger A, Harris P, Payumo F, Motz, Vachanova V. Preliminary Clinical Results of a Phase 1 Study Evaluating the Safety and Anti-Tumor Activity of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ B-Cell Lymphoma. *Blood*. 2018 Nov 29;132(Supplement 1):2966. Poster presentation at: 60th ASH Annual Meeting, December 2018; San Diego, California.
 62. Saygin C, Vaughn JL, Coleman J, Puto M, Roddy J, Penza S, Brammer JE, Efebera Y, Benson DM, Vasu S, Walker AR, Mims AS, Bhatnagar B, Blaser B, Chaudhry M, Choe HK, Larkin K, Long m, Rosko AE, Grieselhuber N, Wall SA, Devine S, Jaglowski S, William BM. Impact of Cytokine Release Syndrome on Outcomes after T-Cell Replete Peripheral Blood Haploidentical Donor Transplantation. *Blood*. 2018 Nov 29;132(Supplement 1):3357. Poster presentation at: 60th ASH Annual Meeting, December 2018; San Diego, California.
 63. Maddocks KJ, Awan FT, Huang Y, Ayyappan S, Baiocchi RA, Epperla N, Jaglowski S, William BM, Blum KA, Christian BA. Preliminary Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. *Blood*. 2018 Nov 29;132(Supplement 1):4185. Poster presentation at: 60th ASH Annual Meeting, December 2018; San Diego, California.
 64. Maakaron J, Penza S, El Blghdadly A, Jacobson CA, Hunter B, Frigault MJ, Abramson JS, Kline J, Cohen JB, Gopal AK, Acharya UH, Jaglowski S, Armand P. Procalcitonin as a Potential Biomarker for Differentiating Bacterial Infectious Fevers from Cytokine Release Syndrome. *Blood*. 2018 Nov 29;132(Supplement 1):4216. Poster presentation at: 60th ASH Annual Meeting, December 2018; San Diego, California.
 65. Merryman RW, Castagna L, Corradini P, Ho VT, Bond DA, Jaglowski S, Spinner MA, Arai S, Lowsky R, Herrera AF, Guidetti A, Ghouse G, Blaise D, De Colella J, Badar R, Hamadani M, Ansell SM, Nieto Y, Spilleboudt C, Feldman TA, Dahncke L, Singh AK, McGuirk JP, Mohty M, Dulery R, Bastard AS, Houot R, Manson G, Moles M, Orvain C, Bouabdallah K, Frigault MJ, Chen Y, Lynch RC, Smith SD, Rao U, Byrne MT, Romancik J, Cohen JB, Joyce RM, Rahimian M, Bashey A, Ballard HJ, Svoboda J, Giordano L, Torri V, Casadei B, Sollini M, De Philippis C, Magagnoli M, Santoro A, Armand P, Zinzani P, Carlo-Stella C. Safety and Efficacy of Allogeneic Hematopoietic Stem Cell Transplant after Programmed Cell Death 1 (PD-1)/Programmed Cell Death Ligand 1 (PD-L1) Blockade for Classical Hodgkin Lymphoma: Analysis of a Large International Cohort. *Blood*. 2019 Nov 13;134(Supplement 1):775. Poster presentation at: 61st ASH, December 2019; Orlando, Florida.
 66. Maakaron J, Zhao Q, Puto M, Verfuth Q, Penza S, Brammer JE, Efebera YA, Rosko AE, Saad A, Jaglowski S, William BM. Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed by Autologous

- Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL). *Blood*. 2019 Nov 13;134(Supplement 1):656. Poster presentation at: 61st ASH, December 2019; Orlando, Florida.
67. Vachanova V, Tam CS, Borchmann P, Jaeger U, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Andreadis C, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles G, Schuster SJ, Maziarz RT, Van Besien K, Izutsu K, Kersten MJ, Magenau JM, Wagner-Johnston ND, Kato K, Corradini P, Chu J, Gershgorin I, Choquette T, Pacaud L, Jeschke M. Impact of Tisagenlecleucel Chimeric Antigen Receptor (CAR)-T Cell Therapy Product Attributes on Clinical Outcomes in Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL). *Blood*. 2019 Nov 13;134(Supplement 1):242. Poster presentation at: 61st ASH, December 2019; Orlando, Florida.
68. Munoz J, Jaglowski S, McKinney MS, Isufi I, Stiff PJ, Sachs J, Ranger A, Harris P, Payumo F, Akard LP. A Phase 1 Study of ACTR087 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20-Positive B-Cell Lymphoma. *Blood*. 2019 Nov 13;134(Supplement 1):244. Poster presentation at: 61st ASH, December 2019; Orlando, Florida.
69. Flinn IV, Westin JR, Cohen JB, Akard LP, Jaglowski S, Sachs J, Ranger A, Harris P, Payumo F, Bachanova V. Preliminary Clinical Results from a Phase 1 Study of ACTR707 in Combination with Rituximab in Subjects with Relapsed or Refractory CD20+ Non-Hodgkin Lymphoma. *Blood*. 2019 Nov 13;134(Supplement 1):1587. Poster presentation at: 61st ASH, December 2019; Orlando, Florida.
70. Sharma N, Ni B, Zhao Q, Elder P, Benson DM, Rosko AE, Chaudhry M, Bumma N, Khan AM, Devarakonda S, Vasu S, Jaglowski S, William BM, Mims AS, Choe HK, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA. Effect of Early Post-Transplantation Tacrolimus Concentration on the Risk of Acute Graft-Versus-Host Disease in Allogeneic Stem Cell Transplantation. *Blood*. 2019 Nov 13;134(Supplement 1):4549. Poster presentation at: 61st ASH, December 2019; Orlando, Florida.
71. Stephens DM, Huang Y, Agyeman A, Ruppert AS, Hu B, Turner N, Vadeboncoeur R, Rogers KA, Bhat SA, William BM, Jaglowski S, Lockman H, Glenn M, Lapalombella R, Byrd JC, Woyach J. Selinexor Combined with Ibrutinib Demonstrates Tolerability and Efficacy in Advanced B-Cell Malignancies: A Phase I Study. *Blood*. 2019 Nov 13;134(Supplement 1):4310. Poster presentation at: 61st ASH, December 2019; Orlando, Florida.
72. Jagers J, Klepin HD, Wildes TM, Olin RL, Artz AS, Wall SA, Jaglowski S, William BM, Benson DM, Rosko AE. Characterizing Inclusion and Exclusion Criteria in Clinical Trials for CAR-T Cellular Therapy Among Adults with Hematologic Malignancies. *Blood*. 2019 Nov 13;134(Supplement 1):5819. Poster presentation at: 61st ASH, December 2019; Orlando, Florida.
73. Christian BA, Huang Y, Ayyappan S, Baiocchi RA, Brammer JE, Epperla N, Jaglowski S, William BM, Awan FT, Maddocks JK, Blum KA. Results of a Phase I Study of Obinutuzumab, Venetoclax, and Lenalidomide in Relapsed and Refractory B-Cell Non-Hodgkin Lymphoma. *Blood*. 2019 Nov 13;134(Supplement 1):4082. Poster presentation at: 61st ASH, December 2019; Orlando, Florida.
74. Westin JR, Tam CS, Borchmann P, Jaeger U, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Andreadis B, Foley SR, Fleury I, Ho PJ, Mielke S, Teshima T, Schuster SJ, Bachanova V, Maziarz RT, Van Besien K, Izutsu K, Kersten MJ, Magenau JM, Wagner-Johnston, Kato K, Corradini P, Han X, Tiwari R, Agoulnik S, Eldjerou LK, Pacaud L, Salles GA. Correlative Analyses of Patient and Clinical Characteristics Associated with Efficacy in Tisagenlecleucel-Treated Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients in the Juliet Trial. *Blood*. 2019 Nov 13;134(Supplement 1):4103. Poster presentation at: 61st ASH, December 2019; Orlando, Florida.
75. Andreadis C, Tam CS, Borchmann P, Jaeger U, McGuirk JP, Holte H, Waller EK, Jaglowski S, Bishop MR, Foley SR, Westin JR, Fleury I, Ho PJ, Mielke S, Teshima T, Salles GA, Schuster SJ, Bachanova V, Maziarz RT, Van Besien K, Izutsu K, Magenau JM, Wagner-Johnston N, Kato K, Corradini P, Tiwari R, Awasthi R, Lawniczek T, Eldjerou LK, Kersten MJ. Correlation of Bridging and Lymphodepleting Chemotherapy with Clinical Outcomes in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Treated with Tisagenlecleucel. *Blood*. 2019 Nov 13;134(Supplement 1):2883. Poster presentation at: 61st ASH, December 2019; Orlando, Florida.
76. Jaglowski S, Hu Z, Zhang Y, Kamdar M, Ghosh M, Lulla P, Sasine J, Perales M, Hematti P, Nikiforow S, Steinert P, Jeschke M, Yi L, Chawla R, Pacaud L, Horowitz M, Bleickardt E, Pasquini MC. Tisagenlecleucel Chimeric Antigen Receptor (CAR) T-Cell Therapy for Adults with Diffuse Large B Cell Lymphoma (DLBCL): Real World Experience from the Center for International Blood and Marrow Transplant Research (CIBMTR) Cellular Therapy (CT) Registry. *Blood*. 2019 Nov 13;134(Supplement 1):766. Oral poster presentation at: 61st ASH, December 2019; Orlando, Florida.

77. Jacobson CA, Locke FL, Miklos DB, Vose JM, Lin Y, Budde LE, Maloney DG, Jaglowski S, Riedell PA, Lekakis LJ, Perales MA, Kim JJ, Kawashima J, Yang Y, Rossi JM, Goyal L, Neelapu SS. Outcomes of Patients (Pts) in ZUMA-9, a Multicenter, Open-Label Study of Axicabtagene Ciloleucel (Axi-Cel) in Relapsed/Refractory Large B Cell Lymphoma (R/R LBCL) for Expanded Access and Commercial Out-of-Specification (OOS) Product. *Blood*. 2020 Nov 5;136(Supplement 1):2–3. Poster presentation at: 62nd ASH Annual Meeting, December 2020.
78. Jiang J, Zhao Q, Sigmund AM, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, William BM, Mims AS, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera Y, Sharma N. Impact of Chronic Graft-Versus-Host Disease on Non-Relapse Mortality. *Blood*. 2020 Nov 5;136(Supplement 1):42. Poster presentation at: 62nd ASH Annual Meeting, December 2020.
79. Sigmund AM, Jiang J, Zhao Q, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, William BM, Mims AS, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N. Improvement in Survival of AML and MDS Patients Following Allogeneic Transplant: A Long-Term Institutional Experience. *Blood*. 2020 Nov 5;136(Supplement 1):30. Poster presentation at: 62nd ASH Annual Meeting, December 2020.
80. Bajwa A, Zhao Q, Coleman J, Brammer JE, Choe H, Efebera YA, Larkin K, Mims AS, Penza S, Saad A, Vasu S, Wall SA, Jaglowski S. A Retrospective Analysis of Outcomes Following Allogeneic Stem Cell Transplantation for Patients from Appalachian Counties. *Blood*. 2020 Nov 5;136(Supplement 1):20–21. Poster presentation at: 62nd ASH Annual Meeting, December 2020.
81. Sigmund AM, Zhao Q, Jiang J, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, William BM, Mims AS, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N. Impact of Race and Geographic Location on Outcomes in Allogeneic Transplant. *Blood*. 2020 Nov 5;136(Supplement 1):17–18. Poster presentation at: 62nd ASH Annual Meeting, December 2020.
82. Sorror NN, Keiter A, Zhao Q, Roddy J, Penza S, Brammer JE, Efebera YA, Benson DM, Vasu S, Mims AS, Blaser BW, Choe H, Larkin K, Grieselhuber N, Wall SA, Saad A, Rosko A, Elder P, Chaudhry M, Bumma N, Khan A, Devarakonda S, Jaglowski S, William BM. Survival Implications of Opioid Use after Blood and Marrow Transplantation. *Blood*. 2020 Nov 5;136(Supplement 1):2–3. Poster presentation at: 62nd ASH Annual Meeting, December 2020.
83. Wang M, Munoz J, Goy AH, Locke FL, Jacobson CA, Hill BT, Timmerman JM, Holmes H, Jaglowski S, Flinn IW, McSweeney PA, Miklos DB, Pagel JM, Kersten MJ, Milpied N, Fung HCH, Topp MS, Houot R, Beitinjaneh A, Peng W, Zheng L, Rossi JM, Murugappan S, Kloos I, Reagan PM. One-Year Follow-up of ZUMA-2, the Multicenter, Registrational Study of KTE-X19 in Patients with Relapsed/Refractory Mantle Cell Lymphoma. *Blood*. 2020 Nov 5;136(Supplement 1):20–22. Poster presentation at: 62nd ASH Annual Meeting, December 2020.
84. Wang M, Rossi JM, munoz J, Goy AH, Locke FL, Reagan PM, Jacobson CA, Hill BT, Holmes H, Jaglowski S, Peng W, Zheng L, Fang X, Xue A, Kloos I, Bot A. Pharmacological Profile and Clinical Outcomes of KTE-X19 By Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Exposure or Mantle Cell Lymphoma (MCL) Morphology in Patients With Relapsed/Refractory (R/R) MCL in the ZUMA-2 Trial. *Blood*. 2020 Nov 5;136(Supplement 1):29. Poster presentation at: 62nd ASH Annual Meeting, December 2020.
85. Jiang J, Sigmund AM, Zhao Q, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, William BM, Mims AS, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Efebera YA, Sharma N. Trend in Survival in Patients Undergoing Allogeneic Stem Cell Transplantation: An Institutional Experience. *Blood*. 2020 Nov 5;136(Supplement 1):15. Poster presentation at: 62nd ASH Annual Meeting, December 2020.
86. Sharma N, Jiang J, Zhao Q, Elder P, Benson DM, Rosko A, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, William BM, Mims AS, Choe H, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, Sigmund AM, Efebera YA. Comparison of Bone Marrow Versus Peripheral Blood in Haploidentical Transplantation Using Post-Transplant Cyclophosphamide- a Retrospective Analysis. *Blood*. 2020 Nov 5;136(Supplement 1):17–18. Poster presentation at: 62nd ASH Annual Meeting, December 2020.
87. Vasu S, Kromer M, Zhao Q, Choe H, Larkin K, Wall SA, Jaglowski S, Penza S, Brammer JE, Sharma N, Jacob N, de Lima MJG, Welliver M. Utilizing Organ-Sparing Marrow Irradiation to Condition Patients Prior to Allogeneic Hematopoietic Cell Transplant with High-Risk Hematologic Malignancies: Results of a Pilot Study. *Blood*. 2021 Nov; 138 (Supplement 1): 2856. Poster presented at: 63rd ASH Annual

- Meeting, December 2021; Atlanta, Georgia.
88. Sigmund AM, Denlinger N, Bajwa A, Elder P, Bond DA, Brammer JE, Saad A, Penza S, de Lima MJG, Jaglowski S, Kittai AS. Outcomes of Large B-Cell Lymphoma Patients By Post CAR-T Salvage Regimen at a Single Institution. *Blood*. 2021 Nov; 138 (Supplement 1): 3851. Poster presented at: 63rd ASH Annual Meeting, December 2021; Atlanta, Georgia.
 89. Maakaron J, Zhao Q, Balakrishna JP, Puto M, Ferguson W, Penza S, Brammer JE, Maddocks KJ, Efebera YA, Saad A, Jaglowski S, William BM. Phase I Dose-Escalation Study of Venetoclax Plus BEAM Followed By Autologous Stem Cell Transplant (ASCT) for Chemoresistant or High-Risk Relapsed/Refractory Non-Hodgkin Lymphoma (NHL). *Blood*. 2021 Nov; 138 (Supplement 1): 656. Poster presented at: 63rd ASH Annual Meeting, December 2021; Atlanta, Georgia.
 90. Shouse G, Kaempf A, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald L, Bajwa A, Jaglowski S, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Kittai AS, Danilov AV. Impact of Comorbidities on Outcomes and Toxicity in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Rwe Study. *Blood*. 2021 Nov; 138 (Supplement 1): 529. Poster presented at: 63rd ASH Annual Meeting, December 2021; Atlanta, Georgia.
 91. Malik SU, Braunstein Z, Vasu S, Penza S, Saad A, Denlinger N, de Lima MJG, Vallakati A, Baliga R, Jaglowski S, Brammer JE, Addison D. Cardiac Arrhythmias and Mortality after Hematopoietic Stem Cell Transplant (HSCT): A Systematic Review and Meta-Analysis. *Blood*. 2021 Nov; 138 (Supplement 1): 2918. Poster presented at: 63rd ASH Annual Meeting, December 2021; Atlanta, Georgia.
 92. Landsburg DJ, Frigault MJ, Hu ZH, Jaglowski S, Locke FL, Ho C, Perales MA, Jacobson C, Hill BT, Foley SR, Riedell PA, Tiwari R, Masood A, Lim S, Majdan M, Pasquini MC, Turtle CJ. Real-World Efficacy and Safety Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Update from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. *Blood*. 2021 Nov; 138 (Supplement 1): 429. Poster presented at: 63rd ASH Annual Meeting, December 2021; Atlanta, Georgia.
 93. Elsayy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, Osman K, Davison K, Rudzki JD, Dahiya S, Dorritie K, Jaglowski S, Radford J, Morschhauser F, Cunningham D, Garcia-Sancho AM, Tzachanis D, Ulrickson ML, Karmali R, Kekre N, Thieblemont C, Enblad G, Dreger P, Malladi R, Joshi N, Wang WJ, Solem CT, Snider JT, To C, Kersten MJ. Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). *Blood*. 2021 Nov; 138 (Supplement 1): 430. Poster presented at: 63rd ASH Annual Meeting, December 2021; Atlanta, Georgia.
 94. Sigmund AM, Jiang J, Zhao Q, Elder P, Rosko AE, Chaudhry M, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims AS, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, de Lima MJG, Benson DM, Efebera YA, Sharma N. Effect of Age on Outcomes of Allogeneic Transplantation in Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Blood*. 2021 Nov; 138 (Supplement 1): 3933. Poster presented at: 63rd ASH Annual Meeting, December 2021; Atlanta, Georgia.
 95. Wang M, Munoz J, Goy A, Locke FL, Jacobson CA, Hill BT, Timmerman J, Holmes H, Jaglowski S, Flinn I, McSweeney PA, Miklos DB, Kersten MJ, Bouabdallah K, Topp MS, Shen R, Kloos I, Peng W, Fang X, Reagan PM. Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24). Poster session presented at: 2021 ASCO Annual Meeting. June 4-8; Online.
 96. Fitch TJ, Huber J, Flesch L, Jaglowski S, Auletta JJ, Lehmann LE, Bhatt NS, Mueller M, Rotz SR, Phelan R, Sigmund AM, Tarquini S, Demmel KM, Dodd T, Liberio N, Maakaron JE, Hayward M, Hartley D, Kusnier K, Myers KC, Krupski MC, Porter J, Craig K, Neal A, Patel SS, Sper C, Pai A, Parker LM, Jakubowski R, Blacken R, Kapadia M, Dandoy CE. Defining Patient-Important Outcomes after Pediatric Hematopoietic Stem Cell Transplant. *Transplantation and Cellular Therapy*. 2022; 28(Supplement 3): S399-S400. Poster presented at: 2022 Tandem Meetings of ASTCT and CIBMTR, April 2022; Salt Lake City, Utah.
 97. Faisal MS, Saad A, Mims A, Vasu S, Wall SA, Larkin K, Choe H, Brammer JE, Penza S, Jaglowski S, De Lima M. Bamlanivimab Monoclonal Antibody Treatment in Patients with Graft Versus Host Disease (GVHD) Diagnosed with COVID-19 Infection. *Transplantation and Cellular Therapy*. 2022;

- 28(Supplement 3): S386-S387. Poster presented at: 2022 Tandem Meetings of ASTCT and CIBMTR, April 2022; Salt Lake City, Utah.
98. Vasu S, Kromer M, Zhao Q, Choe H, Larkin K, Wall SA, Jaglowski S, Penza S, Brammer JE, Sharma N, Jacob N, De Lima M, Welliver M. Utilizing Organ-Sparing Marrow Irradiation to Condition Patients Prior to Allogeneic Hematopoietic Cell Transplant with High-Risk Hematologic Malignancies: Results of a Pilot Study. *Transplantation and Cellular Therapy*. 2022; 28(Supplement 3): S236. Poster presented at: 2022 Tandem Meetings of ASTCT and CIBMTR, April 2022; Salt Lake City, Utah.
99. Elsayy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, Osman K, Davison K, Rudzki JD, Dahiya S, Dorritie K, Jaglowski S, Radford J, Morschhauser F, Cunningham D, Garcia-Sancho AM, Tzachanis D, Ulrickson ML, Karmali R, Kekre N, Thieblemont C, Enblad G, Dreger P, Malladi R, Joshi N, Wang WJ, Solem CT, Snider JT, To C, Kersten MJ. Patient-Reported Outcomes (PROs) in Zuma-7, a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard-of-Care (SOC) Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (LBCL). *Transplantation and Cellular Therapy*. 2022; 28(Supplement 3): S190-S191. Poster presented at: 2022 Tandem Meetings of ASTCT and CIBMTR, April 2022; Salt Lake City, Utah.
100. Denlinger N, Sigmund AM, Huang Y, Bajwa A, Elder P, Brammer JE, Saad A, De Lima M, Jaglowski S, Kittai A. Outcomes of Salvage Therapy after Failure of Anti-CD19 CAR T-Cell Therapy for Diffuse Large B-Cell Lymphoma. *Transplantation and Cellular Therapy*. 2022; 28(Supplement 3): S183-S184. Poster presented at: 2022 Tandem Meetings of ASTCT and CIBMTR, April 2022; Salt Lake City, Utah.
101. Sigmund AM, Jiang J, Zhao Q, Elder P, Rosko A, Bumma N, Khan A, Devarakonda S, Vasu S, Jaglowski S, Mims A, Choe H, Larkin K, Brammer JE, Wall SA, Grieselhuber N, Saad A, Penza S, De Lima M, Benson DM, Efebera Y, Sharma N. Allogeneic Transplantation in Older Patients with Acute Myeloid Leukemia and Myelodysplastic Syndrome. *Transplantation and Cellular Therapy*. 2022; 28(Supplement 3): S115-S116. Poster presented at: 2022 Tandem Meetings of ASTCT and CIBMTR, April 2022; Salt Lake City, Utah.
102. Mian A, Wei W, Chakraborty R, Yi JC, Preussler JM, Hill BT, Cerny J, Deol A, Hahn TE, Hashmi SK, Jaglowski S, Jim HSL, Khera N, Loren AW, McGuirk JP, Savani BN, Stiff P, Uberti JP, Whalen V, Wingard JR, Reynolds J, Holtan SG, Wood WA, Baker KS, Syrjala KL, Hamilton BK, Majhail NS. Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation for Hodgkin and Non-Hodgkin Lymphoma: Secondary Analysis from Two Multi-Center Randomized Controlled Trials of Hematopoietic Cell Transplant Survivorship Interventions. *Blood*. 2022 Nov 15;140(Supplement 1):8019–8021. Poster presented at: 64th ASH Annual Meeting, December 2022; New Orleans, Louisiana.
103. Rosko AE, Dvorak K, Zhao Q, Paskett E, Jaglowski S, Fisher JL, Krok-Schoen J, Cottini F, Khan A, Devarakonda S, Bumma N, Umyarova E, Sharma N, Benson DM, Plascak J. Multiple Myeloma Transplant: Examining the Intersection of Access, Age and Race. *Blood*. 2022 Nov 15;140(Supplement 1):5170–5171. Poster presented at: 64th ASH Annual Meeting, December 2022; New Orleans, Louisiana.
104. Khurana A, Bailey M, Iqbal M, Bansal R, Lee CJ, Hunter B, Lunning MA, Jaglowski S, Jain MD, Dahiya S, Bachanova V, Farooq U, Ahmed S, Hill BT, Munoz JL, Patel K, Oluwole OO, Lin Y. Prophylactic Corticosteroid Use with Axicabtagene Ciloleucel (axi-cel) in Patients with Relapsed/Refractory Large B-Cell Lymphoma (R/R LBCL): Real-World Practice Patterns and Outcomes. *Blood*. 2022 Nov 15;140(Supplement 1):4657–4660. Poster presented at: 64th ASH Annual Meeting, December 2022; New Orleans, Louisiana.
105. Shouse G, Kaempf A, Gordon MJ, Yashar D, Sigmund AM, Smilnak G, Bair SM, Mian A, Fitzgerald LA, Bajwa A, Jaglowski S, Bailey N, Shadman M, Patel K, Stephens DM, Kamdar M, Hill BT, Gauthier J, Karmali R, Nastoupil LJ, Kittai AS, Danilov AV. Impact of a Validated Composite Comorbidity Score on Outcomes in Patients Treated with CAR T-Cell Therapy for Diffuse Large B Cell Lymphoma (DLBCL): A Multicenter Real-World Evidence (RWE) Study. *Blood*. 2022 Nov 15;140(Supplement 1):2048–2050. Poster presented at: 64th ASH Annual Meeting, December 2022; New Orleans, Louisiana.
106. Hosing C, McLaughlin E, Braunstein Z, Valdez BC, Wei L, Popat UR, Andersson BS, Vasu S, Larkin KT, Jaglowski S, Penza S, Saad A, Choe H, Wall SA, Cash A, Nakkula R, Champlin RE, de Lima MJG, Lee DA, Brammer JE. Post-Allograft Romidepsin Maintenance Mitigates Relapse Risk and Stimulates the Graft-Versus-Malignancy Effect through Enhanced NK-Cell Cytotoxicity in Patients with

- Aggressive T-Cell Malignancies in a Phase I/II Trial. *Blood*. 2022 Nov 15;140(Supplement 1):1885–1886. Poster presented at: 64th ASH Annual Meeting, December 2022; New Orleans, Louisiana.
107. Landsburg DJ, Frigault M, Heim M, Foley SR, Hill BT, Ho CM, Jacobson CA, Jaglowski S, Locke FL, Ram R, Riedell PA, Shah GL, Popplewell LL, Tiwari R, Lim S, Majdan M, Masood A, Pasquini MC, Turtle CJ. Real-World Outcomes for Patients with Relapsed or Refractory (R/R) Aggressive B-Cell Non-Hodgkin's Lymphoma (aBNHL) Treated with Commercial Tisagenlecleucel: Subgroup Analyses from the Center for International Blood and Marrow Transplant Research (CIBMTR) Registry. *Blood*. 2022 Nov 15;140(Supplement 1):1584–1587. Poster presented at: 64th ASH Annual Meeting, December 2022; New Orleans, Louisiana.
108. Agrima Mian, Wei Wei, Rajshekhar Chakraborty, Jean Yi, Jaime M. Preussler, Brian T. Hill, Jan Cerny, Abhinav Deol, Theresa E. Hahn, Shahrukh K. Hashmi, Samantha Jaglowski, Heather S.L. Jim, Nandita Khera, Alison W. Loren, Joseph P. McGuirk, Bipin Savani, Patrick Stiff, Joseph Uberti, Victoria Whalen, John R Wingard, Jana Reynolds, Shernan Grace Holtan, William Allen A. Wood, Scott Baker, Karen L. Syrjala, Betty K. Hamilton, Navneet S. Majhail, 493 - Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation (AHCT) for Hodgkin (HL) and Non-Hodgkin Lymphoma (NHL): Secondary Analysis from Two Multicenter Randomized Controlled Trials (RCT) of Hematopoietic Cell Transplant Survivorship Interventions, Transplantation and Cellular Therapy, Volume 29, Issue 2, Supplement, 2023, Pages S369-S370, Poster presented at 2023 Tandem Meeting of ASTCT, February 2023, Orlando Florida.
109. Elizabeth Greer Miller, Maciej Pietrzak, Rebecca Pearson, Jonathan E. Brammer, Marcos de Lima, Samantha Jaglowski, Sam Penza, Sumithira Vasu, Sarah A. Wall, Gerard Lozanski, Hannah Choe, 370 - Evaluating Diversity of Tcrvb Repertoire and Steroid Responsiveness in Acute Graft Versus Host Disease, Transplantation and Cellular Therapy, Volume 29, Issue 2, Supplement, 2023, Pages S280-S281, Poster presented at 2023 Tandem Meeting of ASTCT, February 2023, Orlando Florida.

Patents

1. U.S. Patent 15/538,279: "BTK Inhibitor Combinations and Dosing Regimen," June 21, 2017